Skip to content

Trading Analysis Report: QCOM

  • Analysis date: 2026-10-14
  • Rating: Underweight
  • Generated: 2026-10-14 15:03:06
  • TradingAgents 0.6.0: anthropic, deep claude-opus-5-5, quick claude-sonnet-5-5
  • Analysts: market, sentiment, news, fundamentals; research debate rounds 5, risk debate rounds 5
  • Data vendors: core_stock_apis yfinance, technical_indicators yfinance, fundamental_data sec_edgar,yfinance, news_data yfinance, macro_data fred, prediction_markets polymarket

I. Analyst Team Reports

Market Analyst

Current Price: 172.62 Price As Of: 2026-10-14

QCOM (QUALCOMM Incorporated, Nasdaq/NMS) – Technical Analysis as of 2026-10-14

1. Bottom line

The tool output shows a weakening short- and medium-term picture inside a still-intact monthly uptrend. Weekly and daily SuperTrend are both DOWN. Monthly SuperTrend is still UP.

  • Momentum: QCOM has pulled back about 14.5% from the 2026-09-25 close high of 201.97. MACD has turned negative, and RSI is at 42.36, its lowest reading in the 30-day window.
  • Trend position: Today's close of 172.62 is the first close below the 50-day SMA in the window the tool printed (9/14–10/14). It sits just above the nearly flat 200-day SMA.
  • Volatility: ATR has contracted from its late-September peak, but price is still very volatile on a one-year view.
  • Stretch: Nothing is statistically stretched (weekly z = -0.38). There is no oversold "snap-back" signal yet.
  • Reading: The setup is bearish-to-neutral on a tactical basis and decision-relevant near the 168–174 zone, where the 200-SMA, 50-SMA and Bollinger lower band cluster. I'm reporting what the indicators show. The trade decision is for the next agent.

2. Data integrity notes

  • Source of truth: The verified snapshot (latest row 2026-10-14) matches the indicator tool on every overlapping value: close 172.62, 50-SMA 173.98, 200-SMA 168.04, RSI 42.36, MACD -0.81, ATR 7.06. I found no discrepancies.
  • Indicators outside the snapshot: SuperTrend, z-score and OBV come only from the indicator tool.
  • I checked the SuperTrend distances arithmetically against the 172.62 close, and they are internally consistent.
  • I checked OBV against the volume data: the 10/13→10/14 change equals today's volume of 11,129,673.
  • Today's bar may be incomplete. The 2026-10-14 row is dated "today". If the session isn't finished, today's close, volume, OBV, RSI and MACD can still change. Treat the "first close below the 50-SMA" observation as provisional until the bar is final.
  • Currency: Tool output doesn't state it. The Nasdaq listing implies USD.
  • Indicators not pulled: I did not pull td_9, so I have no TD Sequential counts. The z-score is my only stretch gauge.

3. Price structure over the past year (from the OHLCV data)

  • Range and base: QCOM drifted from about 158 (Oct 2025) to a closing low of 122.94 on 2026-04-07 (intraday low 120.88).
  • Single-day gaps and volume spikes:
  • 2025-10-27: close 183.85 on 81.8M shares.
  • 2026-02-05: opened at 130.87 after a 146.60 close, on 30.2M shares.
  • 2026-04-30: close 177.95 on 61.1M shares.
  • 2026-07-30: opened at 145.76 after a 154.84 close.
  • The tools have no news or earnings calendar, so I can't attribute causes. The gap-and-volume pattern is consistent with quarterly-report or catalyst-driven moves, and event risk looks large for this name.
  • Parabolic leg: The close went from 122.94 (4/7) to 248.74 (5/29), about +102%. It was followed by a drop to a closing low of 146.81 on 7/31, about -41% from the 5/29 close (intraday low 142.12 on 8/3).
  • Rebuild and breakout: QCOM based in the roughly 157–170 range through August. It broke out in September, with closes of 174.09 on 9/8 and 187.80 on 9/15, and peaked at a 201.97 close on 9/25.
  • Current pullback: QCOM has since fallen in 12 of the last 14 sessions to 172.62, giving back about 14.5% from the 9/25 close.
  • 9/28 was -7.2% (201.97 → 187.48).
  • Today's close is -2.4% (176.86 → 172.62), after a failed bounce on 10/13 (intraday high 180.78, close 176.86).

4. Indicator analysis

Trend

SuperTrend (weekly > monthly > daily)

Tier Direction Stop Close vs. stop
Weekly (primary) DOWN 223.47 -22.75%
Monthly (regime) UP 116.41 +48.29%
Daily (timing) DOWN 194.48 -11.24%
  • Weekly and daily agree on DOWN. Per the weighting rule, the primary trend is down, and the daily trend confirms it.
  • The monthly UP trend is a long-horizon regime backdrop. Its stop is 48% below price, so it offers almost no practical risk guidance.
  • Flip distances:
  • A daily flip to UP needs a close above 194.48, about 12.7% higher.
  • A weekly flip needs a close above 223.47, about 29.5% higher.
  • Neither is near, so trend-following tools won't turn constructive soon.

Moving averages (snapshot)

Average Value Close vs. average
10 EMA 177.99 Below (about -3.0%)
50 SMA 173.98 Below (about -0.8%)
200 SMA 168.04 Above (about +2.7%)
  • The 50-SMA is above the 200-SMA, so the long-term configuration is still bullish.
  • The 50-SMA is rising slowly, from 167.90 on 9/14 to 173.98 on 10/14. The 200-SMA is nearly flat, from 166.55 to 168.04 over the same period.
  • Price closed below the 10-EMA and the 50-SMA today. Both averages are now overhead, and price is sitting on the 200-SMA zone.
  • The 50-SMA is rising toward price. If price keeps falling, the 50-SMA stops acting as support and starts acting as resistance.

Momentum

MACD - The line is -0.81, the signal is 1.34, and the histogram is -2.15. - The line peaked at 8.12 on 9/25. It has made 13 consecutive lower readings since then. - It crossed below zero on 10/13 (-0.25, after +0.03 on 10/12). - The decline sped up on the last print: -0.28 on 10/13, then -0.55 on 10/14. - This is a bearish momentum regime. It is not a stretched extreme, so it could grind lower.

RSI (14) - RSI is 42.36, the lowest value in the 9/14–10/14 window. - It peaked at 70.40 on 9/15, the only overbought reading in the window. - It has been below 50 since 10/5 (49.08). - It is nowhere near the 30 oversold threshold. The momentum pullback may have further to run before a statistical oversold signal appears.

Volatility

ATR (14) - ATR is 7.06, about 4.1% of price. - It has contracted from 9.12 on 9/28. The selling is orderly, with narrower ranges than the late-September swings. - Reference stop distances (my arithmetic, not a signal): - 1.5× ATR is about 10.6, or about 162.0 from today's close. - 2× ATR is about 14.1, or about 158.5.

Bollinger Bands (snapshot)

Band Value
Upper 202.00
Middle (20-SMA) 184.47
Lower 166.93
  • Price is in the lower half of the bands. It is about 5.7 above the lower band, roughly 16% of the way up the band range.
  • The bands are wide because of the September rally and the 9/28 drop. The upper band (202.00) is almost exactly the 9/25 high close (201.97).
  • The lower band (166.93) is close to the 200-SMA (168.04).

Volume

OBV - OBV is 545.7M. It peaked at 641.0M on 9/17, before price peaked, and was 615.5M on 9/25. - OBV therefore made a lower high versus the 9/17 reading while price made a higher closing high on 9/25. This is a mild non-confirmation at the top. - Since 9/25, OBV has fallen about 70M alongside price, so volume is confirming the decline. This is not a bullish divergence. - OBV sits just above the window low of 544.6M on 10/12. Price today closed below its 10/12 close of 174.43. The difference is about 0.2%, so I read it as flat, not a divergence.

Raw volume - 10/13 volume was 12.3M and 10/14 is 11.1M, against 6.9M–9.6M on 10/8, 10/9 and 10/12. - Volume rose on the failed bounce and today's reversal. - The 9/18 volume of 54.5M was a down day (188.71 → 177.72) that fully reversed the next session (194.23). 9/18 was a third Friday, which is often an options-expiry or rebalance date. I can't confirm the cause from the tool output.

Mean-reversion stretch (z-score, 20-period)

Timeframe Z-score Reading
Weekly (primary) -0.38 Near the mean
Monthly +0.37 Near the mean
Daily -1.35 Below the mean
  • Daily shows modest downside stretch but is not at the |2| threshold. No timeframe signals an extreme.
  • Weekly near zero says the multi-week move has mostly normalized.

5. Confluence and conflicts

Bearish alignment - Weekly and daily SuperTrend are DOWN. - MACD is negative, and the histogram is -2.15. - RSI is below 50 and at a window low. - Price is below the 10-EMA, the 50-SMA and the Bollinger midline. - OBV declined with price from 9/25.

Offsetting or bullish factors - Monthly SuperTrend is UP. - Price is above a rising 200-SMA, and the 50-SMA is above the 200-SMA. - No oversold or stretched condition has built, and ATR is contracting. - The 10/8 and 10/14 intraday lows are both 171.02, and no new low has been made yet.

Net read: The trend-following and momentum indicators lean bearish. The slow structure is neutral-to-bullish. The key question is whether the cluster of 166.93, 168.04 and 171.02 holds.

6. Reference levels (all from tool output, not validated as support or resistance)

Overhead - 173.98 – 50-SMA - 177.99 – 10-EMA - About 180.8–181.0 – the 10/13 intraday high (180.78) and the 10/5 and 10/6 closes (180.79, 181.03) - 184.47 – Bollinger midline - 187.48 – the 9/28 close - 194.48 – daily SuperTrend stop (a close above flips the daily trend) - 201.97 / 202.00 – the 9/25 high close and the upper Bollinger band

Below - 171.02 – the 10/8 and 10/14 intraday lows - 168.04 – 200-SMA, with the 9/3 and 9/4 closes at 168.57 and 168.74 nearby - 166.93 – lower Bollinger band - About 155–160 – the August lows and closes (8/18 low 155.88, 8/24 low 155.38) - 146.81 / 142.12 – the 7/31 closing low and the 8/3 intraday low

7. Conditional considerations

  • Breakdown case: A decisive daily close below about 166.9–168.0 would remove the Bollinger and 200-SMA cluster. The next reference is the August range near 155–160, which is roughly the 2× ATR distance. The weekly and daily SuperTrend downtrends would remain intact.
  • Stabilization case: Holding above 171.02 and reclaiming the 50-SMA (173.98) and 10-EMA (177.99) would be the first sign the pullback is stalling. MACD would need to flatten and turn up for confirmation. The histogram is still deeply negative, so a quick recovery isn't implied.
  • Trend-restoration case: The daily trend does not flip until a close above 194.48. The weekly trend needs about 223.47. Any rally below those levels remains a counter-trend move under the SuperTrend framework.
  • Sizing: A move of about 4% a day is normal here, and gaps of 10% or more have occurred several times this year. Position size and stop distance should reflect both ATR and gap risk.
  • Event risk: The gaps on ⅖, 4/30 and 7/30 are consistent with quarterly reporting. If that cadence holds, the next report would fall around late October to early November. Verify the date with an event calendar, since my tools don't include one.
  • Dividend: The data shows ex-dividend dates of 12/4/2025 (0.89), ⅗/2026 (0.89), 6/4/2026 (0.92) and 9/3/2026 (0.92). That is a quarterly pattern with a small payout.

8. Summary table

Category Indicator Reading (2026-10-14) Interpretation
Price Close / range 172.62; O 173.63, H 175.61, L 171.02; vol 11.13M Down 2.4% on the day; bar may be incomplete
Trend (primary) SuperTrend weekly DOWN; stop 223.47 (-22.75%) Dominant trend is down
Trend (regime) SuperTrend monthly UP; stop 116.41 (+48.29%) Long-horizon uptrend intact; stop too distant to use
Trend (timing) SuperTrend daily DOWN; stop 194.48 (-11.24%) Confirms weekly; needs a close above 194.48 to flip
Trend 10 EMA 177.99 Price below; short-term resistance
Trend 50 SMA 173.98 Price below; first close under it in the 9/14–10/14 window
Trend 200 SMA 168.04 Price 2.7% above; flat, with 50-SMA above 200-SMA
Momentum MACD / signal / hist -0.81 / 1.34 / -2.15 Bearish; 13 straight declines from 8.12 on 9/25; negative since 10/13
Momentum RSI 42.36 Below 50 since 10/5; window low; not oversold
Volatility ATR 7.06 (about 4.1% of price) Contracting from 9.12 on 9/28
Volatility Bollinger Lower 166.93 / Mid 184.47 / Upper 202.00 Price in the lower half; lower band near the 200-SMA
Volume OBV 545.7M (peak 641.0M on 9/17) Falling with price; no bullish divergence
Stretch Z-score (W / M / D) -0.38 / +0.37 / -1.35 No extreme; modest daily stretch below the mean
Key zone 166.93–171.02 Bollinger lower band, 200-SMA, equal intraday lows Deciding area for the pullback
Overhead 173.98 / 177.99 / about 181 / 184.47 50-SMA, 10-EMA, recent closes, Bollinger midline Layered resistance
Event risk Earnings-style gaps ⅖, 4/30 and 7/30 gaps Next report likely late Oct–early Nov; verify
Data check Snapshot vs. indicator tool All overlapping values match No discrepancies found

Sentiment Analyst

Overall Sentiment: Mixed (Score: 4.8/10) Confidence: Low

Scope and data limits. Window: 2026-10-07 to 2026-10-14 for QCOM (QUALCOMM Incorporated, NMS). Reddit was skipped by config, so there is no Reddit signal and nothing is inferred from it. The news feed is headlines and sources only, with no article bodies or timestamps. StockTwits has 30 messages spanning about 24 hours (2026-10-13 18:31Z to 2026-10-14 18:26Z), so the social read is nearly all from the 10/13-10/14 verdict and reaction window. Earlier days in the week are thinly covered. Confidence is low because one of three sources is absent, news is headline-only, and the StockTwits labels are sparse.

1) Source-by-source breakdown

News (Yahoo Finance, 19 headlines). About 12 are QCOM-specific and about 7 are peer, macro or peripheral (Marvell, Micron x2, TSMC, Intel GPU/Xeon, XCENA, and Barron's on hot CPI). The dominant event is the Delaware jury verdict in Arm v. Qualcomm. It is covered by PR Newswire ('Qualcomm Statement on Trial Verdict Win'), MT Newswires ('Qualcomm Shares Rise After Winning Jury Verdict'), Investing.com ('Arm shares fall after jury rules in favor of Qualcomm'), Stocktwits News and Simply Wall St ('Legal Win Over Arm Could Reshape the Long-Term Thesis'). That is roughly 5-6 event-positive headlines. Zacks ('Qualcomm Rises As Market Takes a Dip') suggests relative strength on at least one down-market day. Against that, 24/7 Wall St runs two skeptical pieces: 'Qualcomm at $175: The Narrative Shift Sending Capital Out The Door' and 'Qualcomm Vs. Intel: The Market is Refuting Both AI Rebrand Attempts'. Trefis asks 'How Much Of Qualcomm Stock Rides On One Business?', which reads as a concentration-risk framing, though the body is not provided. Barchart's 'How to Play Ambarella Stock as Qualcomm Eyes an Acquisition' points to M&A speculation. Whether that is a positive or a negative for QCOM cannot be determined from the headline. The Stocktwits market wrap says Nasdaq fell on a memory-chip selloff with QCOM 'in focus'. Barron's says a hot CPI print puts an October Fed hike back on the table. Net news tone: a positive legal event wrapped in a skeptical valuation and narrative backdrop and a hawkish macro setup.

StockTwits (30 messages). The tagged count is Bullish 5 (17%), Bearish 0 (0%), Unlabeled 25. The 100% bullish split among tagged posts is not informative at n=5. Two Bullish posts are bare '$QCOM' with no body (@noobtraderelite, @InterNativeTradeRs). One (@souldout) is about IQE with QCOM only as a tagalong cashtag. Only two carry QCOM-specific substance: @karuma87 ('back to 200 soon') and @BtcEthBch ('Arm can't increase price now for Qualcomm', a license-terms thesis). The unlabeled body text is more telling. On 10/13 reactions were curious or mildly constructive: @topstockalerts said 'holding up way better than I thought', while @NWMoneymaker asked 'where is that usual sudden god green candle?'. By 10/14 tone had soured. @BRNDN posted 'QCOM lost 10%' and 'just gonna shit the bed huh'. @Unsuccessful wrote 'same knee jerk reaction everytime by wallstreet they dump everything' and 'F. these Algos!'. @theRooster007 said QCOM is 'getting desperate'. @oceanbleu, who had told followers to exit at $201.5, says price is 'almost at target I set for a new long entry', which implies a drop from about $200 and a dip-buyer's mindset. The 'lost 10%' post is ambiguous (the day, a position, or a multi-day move) and no 10/14 price is quoted, so the magnitude of the move is unverified. A bullish options print came from @dustlesspuma: QCOM $182.5 calls expiring Oct 16, 500 contracts ($1.55 each, about $77,500 premium), 5x volume/open interest, a 'repeat sweep', spot $176.61. That is a roughly 3.3% out-of-the-money, 2-day-dated bet. It signals short-term speculative upside positioning but is not a high-conviction long-term signal. Other posts are noise or promotion (@TheNextTrillionaire touting a paid-alert service, @kindness123 and @jgkkgg bare ticker or link posts, recap and news-bot posts).

Reddit. Disabled by config. No data, no inference.

2) Cross-source divergences and alignments - Event vs. price reaction (key divergence). News frames the verdict as a clear win, yet retail commentary points to a muted or negative price response: 'QCOM stalling as if the case outcome fell the other way' (@Unsuccessful), 'where is that green candle', and a hard 10/14 morning selloff. Arm 'rising fast' after hours per one user, despite losing, adds to the sense that the market is not treating the verdict as a big QCOM positive. - Magnitude of the win. Retail summaries of the Reuters report say the jury awarded $2 in nominal damages ($1 per claim). They say Arm failed to provide software patches and tools it owed and interfered with Qualcomm's relationship with Meta. They also say Arm won other claims (the text is truncated, so the detail is not in evidence). @BIOSqueeez says the potentially significant question, a possible five-year royalty suspension, is still open. @Stock_Pumper101 reacted with 'It really is for $2. LOL'. Headline 'win' language therefore likely overstates near-term financial impact. The strategic value (license certainty, deterrence on Arm pricing, Meta relationship) is the bull argument and is only asserted by retail users here. - Tags vs. text. The only labeled sentiment is bullish, but the untagged text from 10/14 is frustrated or bearish. The label ratio overstates bullishness. - Retail dip-buying vs. institutional-style skepticism. @karuma87 and @oceanbleu are eyeing $200 or a re-entry, while 24/7 Wall St argues capital is leaving on a narrative shift and that the AI rebrand is not credited. - Alignment. All sources agree the Arm verdict is the dominant catalyst and that the stock has not been rewarded commensurately. They also agree the tape is under macro and sector pressure.

3) Dominant narrative themes 1. The Arm licensing verdict: a legal win with small damages and unresolved royalty-suspension questions. 2. Price weakness vs. event: QCOM around $175-$177 on 10/13 versus a roughly $200 reference a short time earlier, with further 10/14 weakness per retail posts. 3. Macro: hot CPI and renewed Fed-hike risk pressuring growth and semiconductor multiples, with retail complaining that the market 'dumps everything'. 4. AI-narrative skepticism: 'market is refuting both AI rebrand attempts' (QCOM and Intel) and handset-concentration questions. 5. Sector rotation or selloff: memory-chip weakness, with peer pieces on Marvell, Micron and TSMC reflecting a jittery semi complex. 6. M&A speculation: Ambarella acquisition chatter (unverified, direction ambiguous).

4) Catalysts and risks surfaced by the data - Upside catalysts: a favorable ruling on the open five-year royalty-suspension issue (retail-sourced; the status is not confirmed in the evidence). A clearer license-cost outlook if Arm's leverage is seen as reduced. Short-dated call flow and dip-buyers could support a bounce. Mean reversion toward the $200 retail reference level. - Downside risks: hot CPI and Fed-hike repricing, a continued semiconductor and memory selloff, and the 'capital leaving' narrative. The AI-diversification story is not being credited. Possible Ambarella acquisition may be read as a use-of-cash or strategy concern (speculative). Handset concentration. The verdict's small damages and Arm's wins on other claims limit the financial payoff. Arm's response, such as post-trial motions or appeals, is not in the data. - Not in evidence: upcoming earnings date, analyst rating or price-target changes, actual 10/14 price or volume, and Reddit sentiment. - Retail reference levels: about $176.61 (10/13 spot per options post), $182.5 (call strike), about $200-$201.5 (prior exit and target zone). These are user-quoted and not verified technicals.

5) Summary table of key sentiment signals

Signal Direction Source Supporting evidence
Delaware jury verdict vs. Arm Bullish (event) News: PR Newswire, MT Newswires, Investing.com, Stocktwits News, Simply Wall St Jury found Arm breached the license and interfered with the Meta relationship; QCOM shares rose and Arm fell on the headline
Small economic impact, open royalty question Neutral to cautious StockTwits: @BIOSqueeez, @Stock_Pumper101, @KryptonResearch14 $2 nominal damages ($1 per claim); five-year royalty suspension unresolved; Arm won other claims
Price reaction after verdict Bearish StockTwits: @Unsuccessful, @NWMoneymaker, @BRNDN 'stalling', 'where is that green candle', 'lost 10%' (ambiguous), 'shit the bed'
Narrative and valuation skepticism Bearish News: 24/7 Wall St, Trefis 'Narrative Shift Sending Capital Out The Door' at $175; 'Market is Refuting Both AI Rebrand Attempts'; concentration question
Macro rate risk Bearish News: Barron's; StockTwits: @Techdamentals Hot CPI puts October Fed hike back on the table; CPI discussed in retail posts
Sector and memory selloff Mildly bearish News: Stocktwits market wrap, Trefis peer pieces Nasdaq down on memory-chip selloff with QCOM in focus
Short-dated call flow Mildly bullish StockTwits: @dustlesspuma 500 contracts of $182.5C Oct 16, about $77.5k premium, 5x Vol/OI, repeat sweep, spot $176.61
Tagged retail sentiment Bullish (low reliability) StockTwits 5 Bullish / 0 Bearish / 25 unlabeled of 30; 2 empty bodies, 1 off-topic
Dip-buying and re-entry chatter Mildly bullish StockTwits: @karuma87, @oceanbleu 'back to 200 soon'; near a new long-entry target after exiting at $201.5
Ambarella acquisition speculation Ambiguous News: Barchart 'Qualcomm Eyes an Acquisition'; headline only, direction unclear
Reddit No data Config-disabled No inference possible

Bottom line for the trader: Sources diverge. The verdict is a positive event, but its financial impact looks limited and the market has not rewarded it. Retail tone turned frustrated on 10/14 despite bullish tags, and news carries valuation and macro skepticism. Overall sentiment is Mixed, with a slight bearish tilt in price-reaction evidence offset by dip-buying and bullish short-dated options flow. Low confidence given the missing Reddit data, headline-only news, sparse labels and a very narrow time window. This is sentiment signal only and should be weighed alongside fundamentals and technicals.

News Analyst

QCOM (QUALCOMM Inc., NMS): News and Macro Report for 2026-10-07 to 2026-10-14

Data limits

  • FRED macro data failed. I queried fed_funds_rate, 10y_treasury, cpi, unemployment, yield_curve and vix. Every call returned DATA_UNAVAILABLE because the FRED API key isn't set. I have no CPI print, yield level, unemployment rate or VIX reading, and I haven't estimated any. Macro conclusions below rest on headlines and prediction markets only.
  • The news tool returned headlines and links only. There were no article bodies, dates within the week, price data or figures. I haven't checked claims such as the verdict terms, the Ambarella story or the "$175" price against article text.
  • No QCOM price, volume or technical data came back. I can't give levels.

1. QCOM-specific news

Arm licensing verdict (the main catalyst) - Several headlines say a Delaware jury ruled for Qualcomm in its licensing dispute with Arm. They include the Qualcomm press release ("Qualcomm Statement on Trial Verdict Win"), MT Newswires ("Qualcomm Shares Rise After Winning Jury Verdict"), Investing.com ("Arm shares fall after jury rules in favor of Qualcomm") and Stocktwits. - Market reaction: QCOM rose and Arm fell on the verdict. - Why it matters: The ruling removes a tail risk to Qualcomm's custom-CPU (Oryon) roadmap in PCs, mobile and automotive. It also weakens Arm's leverage over royalty terms with its licensees. - Unknowns: I couldn't see the damages, whether the verdict is final, or whether appeals or post-trial motions are expected. Check those before sizing a position.

M&A speculation - Barchart ran "How to Play Ambarella Stock as Qualcomm Eyes an Acquisition." - The headline frames this as reported interest, not an announced deal. I couldn't verify the source or terms. - An acquisition would raise questions about price paid, dilution, and Qualcomm's push into automotive and edge-AI vision. Treat it as unconfirmed.

Sentiment is mixed to skeptical - 24/7 Wall St. ran "Qualcomm at $175: The Narrative Shift Sending Capital Out The Door." This suggests QCOM trades around $175, but that is from a headline only. - The same outlet ran "Qualcomm Vs. Intel: The Market is Refuting Both AI Rebrand Attempts." It argues investors don't yet credit Qualcomm's AI-compute pivot. - Trefis ran "How Much Of Qualcomm Stock Rides On One Business?" This points to the usual concentration concern, most likely the handset and Snapdragon business. I haven't verified the detail. - Zacks ran "Qualcomm (QCOM) Rises As Market Takes a Dip," so QCOM outperformed on at least one down session. - Insider Monkey asked whether QCOM is "a good or bad investment at today's price," which suggests a live valuation debate.

Sector tape - Stocktwits reported "S&P 500 ends flat, while Nasdaq drops as memory chipmakers sell off," with QCOM and ARM both flagged. - Yahoo Finance's AlphaCheck wrote that "chip stocks fall" even as banks rallied on JPMorgan and Goldman earnings. - Another AlphaCheck piece says tech rebounded as "AI trade jitters ease." - Trefis and 24/7 Wall St. ran pieces on Marvell, Micron and TSMC. These point to pressure on semiconductor valuations and questions about growth durability. - Together, these show the semiconductor group is volatile and sensitive to AI sentiment and yields.

2. Macro backdrop (headline-based)

Inflation and rates: a hawkish shift - Barron's: "Hot CPI Puts an October Fed Rate Hike Back on the Table." I don't have the CPI figure. - Yahoo Finance: "10-year Treasury yield rises following hot inflation data." - Mortgage rates are at the highest level in nearly three years, and one outlet asks "Is 8% next?" - Yahoo Finance headlines say global bond yields are surging, with France on the "ugly side."

Equity risk sentiment - BlackRock is "suddenly more bearish on stocks." - The BofA fund manager survey says investors won't swap stocks for bonds until yields hit 5.9%. The headline doesn't say which yield, but the threshold implies yields are well below that now. - Another headline says "Bubble-like stock valuations and debt crisis chatter aren't exactly bullish."

Energy and geopolitics - Yahoo Finance: "Oil falls to $103 as Trump says US will not attack Iran before the midterm elections." Oil above $100 is an inflationary input and a headwind for tech multiples. - "Tech slumps as oil prices rise, focus turns to earnings season kickoff."

3. Prediction markets (Polymarket)

Market Implied probability Volume Notes
No Fed rate cuts in 2026 97% $8.9M 1-week change +1.1pp. This is the deepest Fed market, so most reliable.
Another Fed hike in 2026 (resolves 12/10) 86% $0.76M 1-week change +8pp
Exactly 1 hike in 2026 14% $0.43M -7pp
Exactly 2 hikes in 2026 64% $0.18M -2.5pp
Exactly 3 hikes in 2026 20% $0.14M +9.8pp
4 hikes / 5+ hikes 1% / 0% thin
US recession by end of 2026 8% $2.3M 1-week change +1pp
US invades Iran before 2027 16% $74M 1-week change +1pp. Very liquid.
Iran leadership change by Dec 31 12% $5.2M
Mojtaba Khamenei head of state at end of 2026 87% $6.7M
Trump says "Qualcomm" in October 52% $252 Negligible volume, so no signal.

How to read these - The market prices no rate cuts in 2026 with near certainty, and further hikes as likely. Recession odds are low at 8%. That combination points to a "higher for longer, possibly higher still" regime without a growth scare. It is bad for long-duration equity multiples and good for the dollar and yields. - The hike-count markets are thin, and their wording is ambiguous. "Another hike" and the count markets together suggest at least one hike may already have happened in 2026, but I can't confirm that. The distribution has also moved in a week, with 3 hikes up about 10pp and 1 hike down 7pp. That is noise-prone, so don't over-read it. - There is no Qualcomm-specific prediction market worth using.

4. Trading takeaways for QCOM

Supportive factors 1. Arm verdict: This is a clear de-risking event for the licensing and custom-silicon thesis. It is the likely driver of the relative strength seen on down days. 2. Resilience on weak tape: Zacks noted QCOM rising while the market fell. 3. Possible M&A: An Ambarella deal would be a strategic diversification move, but it is unconfirmed and carries execution and price risk.

Risks 1. Rates and multiple compression: Hot inflation, rising yields and a hike bias hurt semiconductors broadly. QCOM's dividend-and-buyback profile partly offsets this, though I have no data on its yield. 2. Semiconductor sentiment: Memory and AI-related chip names sold off in the window, and "AI trade jitters" are a recurring theme. QCOM's AI narrative is viewed skeptically, so it may not get the AI premium on rallies. 3. Concentration: The Trefis piece highlights dependence on one business. Check handset-cycle and Apple-modem exposure when judging the next earnings report. 4. Macro shock channels: Oil above $100, Iran tail risk (16% invasion odds) and global bond-yield stress could trigger risk-off moves that hit high-beta tech. 5. Verdict follow-through: Appeals or post-trial motions could reduce the verdict's value. I couldn't verify this.

Catalysts to watch (calendar items below are from general knowledge, not the tools, so verify them) - QCOM's fiscal Q4 earnings, historically early November, and the guidance for the holiday quarter. - The late-October FOMC meeting and the next CPI and jobs data. - Big-tech and semiconductor earnings, including TSMC (typically mid-October), as read-throughs on demand. - Confirmation or denial of the Ambarella report. - Arm's response to the verdict, including appeals. - Oil, the Iran headlines, and the 10-year yield trend.

5. Summary table

Category Key point Source type Implication for QCOM
Company catalyst Delaware jury ruled for Qualcomm in the Arm licensing dispute. QCOM rose and Arm fell. Press release, MT Newswires, Investing.com, Stocktwits Positive. Removes licensing tail risk. Terms and appeal status unverified.
M&A Barchart reports Qualcomm "eyes" an Ambarella acquisition. Barchart headline Unconfirmed. Could add automotive and vision exposure but carries price and dilution risk.
Sentiment Headlines are skeptical of Qualcomm's AI rebrand, cite a roughly $175 price, and flag business concentration. 24/7 Wall St., Trefis, Insider Monkey Valuation debate. Rallies may lack an AI premium.
Sector tape Memory chipmakers sold off, chips fell on some days, and tech rebounded as AI jitters eased. Stocktwits, AlphaCheck Choppy and volatile. QCOM showed relative strength on at least one down day.
Inflation and Fed Hot CPI revived October-hike talk. The 10-year yield rose. Markets give 97% odds of no cuts in 2026 and 86% odds of another hike. Barron's, Yahoo Finance, Polymarket Headwind to equity multiples. The Fed is hawkish.
Growth US recession odds are 8%. Polymarket No growth scare priced, so the risk is stagflation-style higher-for-longer, not a hard landing.
Global rates Bond yields are surging worldwide. Mortgage rates are at a near three-year high. Yahoo Finance Tighter financial conditions.
Equity sentiment BlackRock is more bearish. Valuations are described as bubble-like. Yahoo Finance Higher drawdown risk for high-multiple tech.
Energy and geopolitics Oil is around $103. US invasion of Iran before 2027 is priced at 16%. Yahoo Finance, Polymarket Inflation input and risk-off trigger.
Macro data FRED series (rates, CPI, unemployment, yield curve, VIX) were unavailable. Tool error No quantified macro data. Rely on other sources for levels.
Watch list QCOM earnings (early November, to verify), the late-October FOMC, CPI and jobs, Arm appeal news, Ambarella confirmation. Mixed Event risk clusters in the next 2–4 weeks.

Fundamentals Analyst

QCOM (QUALCOMM Incorporated) Fundamental Report, as of 2026-10-14

1. Scope and data caveats

  • Nothing new in the last 7 days. The latest insider entry is dated 2026-09-30. The latest financial statements cover the quarter ended 2026-06-28, which I label fiscal Q3 FY26. The fiscal year ended around 2026-09-27, but Q4 and the 10-K are not in the data yet. Historically QCOM reports in early November, so confirm the date.
  • Missing fiscal Q4 columns. The income statement skips every September quarter (for example 2025-09-28), so I can't build a trailing twelve months (TTM) figure from the statements. The cash flow statement is cumulative year-to-date (3, 6 and 9 months). I derived the discrete quarters by subtraction.
  • Derived figures. The "Gross Profit" row is "not tagged by this filer", so I computed it as revenue minus cost of revenue. "Implied operating expenses" is gross profit minus operating income. Both are my calculations.
  • Implied share price. The tool prints no spot price. P/E × EPS (19.98 × 8.64) and P/B × book value (6.597 × 26.17) both give about $172.6, so I use that figure.
  • No qualitative data. These tools have no segment or product breakdown and no news, so I can't attribute the numbers to handset, auto, IoT or licensing.

2. Snapshot and valuation

Metric Value Comment
Market cap $184.3B About 1.07B shares
P/E (TTM) / Forward P/E 19.98x / 16.93x TTM is distorted (see §3)
PEG 0.79 Tool-supplied
P/B 6.60x Book value $26.17/share
EPS (TTM) / Forward EPS $8.64 / $10.20 Basis of forward EPS not specified
Dividend yield 2.08% About $3.6/share, roughly $3.8B a year (my estimate)
Beta 1.65 High volatility
52-week range $121.99 – $259.92 Price is about 34% below the high and 41% above the low
50-day / 200-day average $174.15 / $169.36 Price sits between the two, about 1% below the 50-day and 2% above the 200-day
Revenue (TTM) $44.07B
Gross margin (TTM) 54.2% $23.9B gross profit
EBITDA $12.0B
Net income (TTM) $9.26B (21.0% margin) Includes two large offsetting items
Operating margin 18.5% Period basis not stated
ROE / ROA 33.8% / 11.6%
Debt/equity 0.55x Implies about $15.3B of debt
Current ratio 2.02
Free cash flow (TTM) $10.24B About 5.6% FCF yield, 18x price/FCF

Rough EV/EBITDA is about 16x (market cap + about $15.3B debt − $4.5B cash). That is an upper bound, because marketable securities aren't in the balance sheet output.

3. Income statement: revenue is flat but margins are compressing

USD millions. Fiscal quarter labels are mine.

Period end Fiscal Q Revenue Gross profit* Gross margin Op income Op margin Net income Diluted EPS
2024-12-29 Q1 FY25 11,669 6,508 55.8% 3,555 30.5% 3,180 2.83
2025-03-30 Q2 FY25 10,979 6,042 55.0% 3,120 28.4% 2,812 2.52
2025-06-29 Q3 FY25 10,365 5,759 55.6% 2,762 26.6% 2,666 2.43
2025-12-28 Q1 FY26 12,252 6,684 54.6% 3,366 27.5% 3,004 2.78
2026-03-29 Q2 FY26 10,599 5,699 53.8% 2,309 21.8% 7,370 6.88
2026-06-28 Q3 FY26 9,947 5,277 53.1% 1,626 16.3% 2,002 1.87

*Derived.

Year-over-year trend - Revenue: +5.0% in Q1, −3.5% in Q2, −4.0% in Q3. The nine-month total is $32.8B against $33.0B (−0.7%). Q1 FY26 at $12.25B is the highest quarterly revenue in the dataset. - Operating income: −5.3%, −26.0%, then −41.1% in Q3. The nine-month total is $7.30B against $9.44B (−22.6%), and the nine-month operating margin is 22.3% against 28.6%. - Gross margin: down about 2.5 points over six quarters, from 55.8% to 53.1%. - Implied operating expenses: $3,318M, $3,390M and $3,651M in Q1–Q3 FY26. That is +12%, +16% and +22% year over year, against revenue that has turned negative. This is the main driver of the margin squeeze. The tool doesn't say whether restructuring or other one-time items are included. - Q3 EPS: $1.87 against $2.43, down 23%. Net income fell less than operating income (−25% against −41%), so below-the-line items cushioned the result. - Share count: diluted shares are about 1.071B in Q3 FY26 against about 1.097B a year earlier, roughly −2.4%, so buybacks continue.

The Q2 FY26 net income of $7.37B is the biggest distortion. - It is more than three times operating income of $2.31B. The tool doesn't itemize the driver. - Working back from the TTM net income of $9.26B, the implied Q4 FY25 is about −$3.1B (my derivation). - The TTM P/E of 20x therefore sits on a one-time loss and a one-time gain that largely offset. - A cleaner reference is the latest quarter's EPS of $1.87 annualized, about $7.50. That gives roughly 23x GAAP at $172.6, against the 16.9x forward multiple. - The forward EPS basis (GAAP or non-GAAP) is unknown.

4. Balance sheet: solid but loosening

USD millions.

Date Total assets Cash Current assets Current liabilities Current ratio Total liabilities Equity
2025-06-29 54,862 5,448 24,913 7,800 3.19 27,653 27,209
2025-09-28 50,143 5,520 25,754 9,144 2.82 28,937 21,206
2025-12-28 53,034 7,205 24,608 9,822 2.51 29,961 23,073
2026-03-29 57,136 5,435 23,112 9,767 2.37 29,858 27,278
2026-06-28 57,367 4,533 23,004 11,413 2.02 29,709 27,658
  • Liquidity is thinning. The current ratio fell from 2.82 to 2.02 in three quarters. Current liabilities rose 17% in the latest quarter alone, and cash fell 37% from the December 2025 quarter. The tool doesn't show what drove the increase (debt maturities, payables or something else).
  • Leverage is moderate. Total liabilities are about 52% of assets and about 1.07x equity, and debt/equity is 0.55x. Liabilities have been flat at about $28–30B for two years.
  • Non-current assets are up about $10B. They rose from about $24.4B at 2025-09-28 to about $34.4B at 2026-06-28. Equity rose $6.5B over the same stretch, in line with the Q2 net income jump. Operating cash flow did not rise, and nine-month investing outflow was only $1.65B, so the asset growth looks largely non-cash. That is consistent with a tax-related or other non-cash item, but it is unconfirmed. Check the 10-Q.
  • Equity swung. It dropped from $27.2B to $21.2B in the September 2025 quarter (consistent with the implied loss) and recovered to $27.7B.

5. Cash flow: the sharpest deterioration

USD millions. Discrete quarters are derived from the year-to-date figures.

Quarter Operating CF Capex FCF (OCF − capex) FCF year over year
Q1 FY25 4,587 277 4,310 n/a
Q2 FY25 2,554 214 2,340 n/a
Q3 FY25 2,875 294 2,581 n/a
Q1 FY26 4,965 549 4,416 +2.5%
Q2 FY26 2,449 533 1,916 −18.1%
Q3 FY26 991 496 495 −80.8%
  • Nine-month totals (FY26 against FY25):
  • Operating cash flow is $8.41B against $10.02B (−16.1%).
  • Capex is $1.58B against $0.79B (+101%).
  • FCF is $6.83B against $9.23B (−26.0%).
  • FCF margin is 20.8% against 28.0%.
  • Q3 operating cash flow of $991M is down 65% year over year. The tool doesn't say whether this is working capital or tax timing (temporary) or something structural. It is the number to check against the 10-Q.
  • The reported $10.24B TTM FCF flatters the current run-rate. It includes a strong Q4 FY25 (about $3.4B, my derivation). The nine-month pace annualizes to about $9.1B, and the last quarter alone is far weaker.
  • Shareholder returns exceed FCF.
  • Nine-month financing outflow is $10.05B (FY25: $9.76B). It includes buybacks, dividends and any net debt repayment, which aren't itemized.
  • That is about $3.2B more than nine-month FCF, and the cash balance fell.
  • The dividend of about $3.8B a year is well covered, at roughly 37–42% of FCF.
  • Holding total returns near $10B a year with FCF falling would require cash drawdown, borrowing or smaller buybacks.
  • Reconciliation gap. Operating, investing and financing flows don't tie to the change in balance-sheet cash. The gap is about $2.3B in each FY26 year-to-date period. I can't tell why from these outputs, so treat the investing and financing detail as approximate.

6. Insider transactions (data runs 2024-12-09 to 2026-09-30)

  • No open-market purchases appear anywhere in the 150 rows. Everything else is stock grants (director awards and large December executive grants), a gift and unlabeled rows (probably vesting or tax withholding, which I can't confirm).
  • Trailing 12 months (from 2025-10-14): 29 sales, about 115,900 shares and about $20.2M. That is roughly 0.01% of shares outstanding.
Insider Role Sales Shares Value
Akash Palkhiwala COO 12 48,372 $8.18M
Cristiano Amon CEO 3 30,000 $5.60M
Alexander Rogers Officer 1 (Dec 2025) 15,917 $2.83M
Ann Chaplin General Counsel 1 (Dec 2025) 7,180 $1.28M
Heather Ace Officer 4 11,200 $1.75M
Patricia Grech Officer 8 3,231 $0.54M
  • Pre-arranged pattern. The COO sells monthly, around the 2nd–14th of each month. The lot size was 3,333 shares through February 2026 and 2,500 shares from March 2026. The CEO's sales at round prices ($180, $185, $195) look like limit orders. This pattern suggests plan-based selling, but the tool doesn't confirm any plan.
  • CEO sale outside the window. On 2025-10-01 the CEO sold 150,000 shares for $24.8M at about $165–167.
  • Most recent sales (last 90 days): five sales, about $3.4M. The latest is the CEO's 10,000 shares at $195.00 on 2026-09-21, about 13% above the implied current price. The 2026-09-30 entries are small director grants.
  • Signal strength. This is routine selling with no discretionary buying. It is a mild negative at most, and I wouldn't weight it heavily.

7. What the data supports

Supportive - Forward P/E of 16.9x, PEG of 0.79, TTM FCF yield of about 5.6%, and a 2.1% dividend that is well covered. - Revenue is roughly stable over nine months (−0.7%). - Gross margin is still above 53%. - Buybacks are shrinking the share count by about 2–4% a year. - Leverage is moderate (0.55x), and ROE is 33.8% (flattered by one-time items). - Price is about 34% off the 52-week high and near its 50-day and 200-day averages.

Concerning - Operating margin has fallen from 30.5% to 16.3% in six quarters, and operating income is down 41% year over year. Implied operating expenses are growing faster each quarter (+12%, +16%, +22%) while revenue is shrinking. - Q3 operating cash flow and FCF are down 65% and 81% year over year, and capex has doubled. - Distributions exceed FCF, cash is down 37% from December, and the current ratio has dropped from 2.82 to 2.02. - TTM earnings are distorted by about −$3.1B and +$7.4B items. On the latest quarter's run-rate the GAAP P/E is about 23x. - Beta is 1.65 and the 52-week range is $122–$260. - Insiders have been steady sellers with no buying.

What to check next 1. Q4 FY26 results and FY27 guidance (expected early November, confirm the date). Look for whether operating expenses stabilize and operating margin recovers from 16%, and whether operating cash flow rebounds from the $991M quarter. 2. The 10-Q/10-K for the Q2 FY26 $7.4B net income and the Q4 FY25 implied loss. These set the true earnings base. 3. What drove the $1.6B rise in current liabilities, and whether buybacks slow. 4. Insider Form 4 filings after earnings. Watch whether the monthly COO and CEO sales continue.

8. Summary table

Area Key finding Implication
Valuation Price about $172.6; forward P/E 16.9x; TTM P/E 20x; about 23x on latest-quarter run-rate; PEG 0.79; dividend yield 2.08% Cheap on forward numbers, but TTM EPS is distorted
Revenue 9-month −0.7%; Q2 −3.5%, Q3 −4.0% year over year; Q1 FY26 was a record $12.25B Flat to slightly declining
Profitability Gross margin 55.8% → 53.1%; operating margin 30.5% → 16.3%; implied operating expenses +22% year over year in Q3 Main bear signal
Earnings quality Q2 FY26 net income $7.37B against $2.31B operating income; implied Q4 FY25 loss about −$3.1B One-time items distort TTM metrics; verify in filings
Cash flow Q3 operating cash flow $991M (−65%); FCF $495M (−81%); 9-month FCF −26%; capex +101% Weakest area; check working capital against structural causes
Capital returns 9-month financing outflow $10.05B against FCF $6.83B Returns outpacing FCF, funded by cash drawdown
Balance sheet Cash $4.5B (−37% since Dec); current ratio 2.82 → 2.02; debt/equity 0.55x; non-current assets up about $10B Still sound, but liquidity trend is negative
Insiders 29 sales, about $20.2M, about 115,900 shares in 12 months; no purchases; CEO sold at $195 on 2025-09-21 Routine, plan-like selling; mild negative sentiment
Risk Beta 1.65; 52-week range $122–$260; price between the 50-day ($174) and 200-day ($169) averages High volatility around the earnings catalyst
Data gaps No Q4 columns; cash flow doesn't reconcile (about $2.3B gap); gross profit derived; no segment or news data Treat derived figures as approximate

II. Research Team Decision

Bull Researcher

Bull Analyst: # Bull Case for QCOM: The Market Is Pricing a Broken Story, and the Evidence Says It's Merely a Bruised One

Since I'm opening, I'll make my case and answer the objections I expect you to raise.

1. Valuation already assumes the bad news

At about $172.6, QCOM trades at 16.9x forward earnings, a 0.79 PEG, a 5.6% TTM FCF yield and a 2.08% dividend. The stock is 34% below its 52-week high of $259.92. This is not the "bubble-like valuation" the macro headlines warn about. Share count is also shrinking, down about 2.4% year over year, so every dollar of earnings is spread over fewer shares.

I'll concede the TTM P/E of 20x is distorted by a $7.37B net income quarter and an implied Q4 FY25 loss of about $3.1B. Even on the latest quarter annualized (about $7.50 EPS), QCOM is around 23x GAAP. That is a fair multiple for a company with a 33.8% ROE, not a stretched one.

2. The Arm verdict removed the biggest strategic overhang

A Delaware jury ruled for Qualcomm. QCOM rose and Arm fell on the news. This de-risks the custom-CPU (Oryon) roadmap and weakens Arm's leverage over royalty terms.

I know the objection: the reported damages were nominal ($2), and the market shrugged. But the value of the verdict is license certainty, not a cash award. A company can't commit R&D to a CPU roadmap while its core license is in dispute. That uncertainty is now much smaller. Retail sentiment says the market hasn't rewarded this yet, and I'd call that an opportunity. Appeal status is unverified, so I'm not claiming this is closed.

3. The margin story is an opex problem, not a franchise problem

The bear case will lead with operating margin falling from 30.5% to 16.3%. Look at where the damage is:

  • Q3 FY26 gross margin was 53.1%, against 55.6% a year earlier, a decline of 2.5 points.
  • Operating margin fell 10.3 points over the same period.
  • About three-quarters of the compression, roughly 7.8 points, comes from operating expenses, which rose from about 29% to 37% of revenue.

The pricing power and product economics are intact, with gross margin still above 53%. The squeeze comes from spending growth (+22% year over year) running ahead of a flat revenue line. Spending is a lever management controls. Revenue was flat over nine months (−0.7%), and Q1 FY26's $12.25B was the highest quarterly revenue in the dataset. At that revenue level, Q1 operating margin was 27.5%. The earnings power is there, and the question is cost discipline, which the early-November print will address.

I can't say from this data whether that spending is investment in PCs, auto or AI compute or simply bloat. If the Arm win makes the custom-silicon bet more defensible, the spend looks better.

4. Cash flow: one ugly quarter doesn't erase a $9B annual run-rate

Q3 operating cash flow of $991M is the bear's best number, and I won't hide from it. But:

  • Nine-month FCF is still $6.83B, about $9.1B annualized, or roughly a 4.9% yield on the current market cap.
  • The dividend (about $3.8B) takes only 37–42% of that FCF.
  • The data doesn't say whether Q3 was working capital and tax timing or something structural. The 10-Q will answer that. Until then, a one-quarter anomaly isn't a trend.
  • Capex doubling is a choice. It is growth investment, not distress.

The balance sheet is sound. Debt/equity is 0.55x, the current ratio is 2.02 and equity has recovered to $27.7B. Liquidity is thinning but nowhere near stress.

5. The technicals show a pullback inside an intact structure

Weekly and daily SuperTrend are DOWN, and I won't pretend otherwise. But:

  • Monthly SuperTrend is UP, and the 50-SMA is above the 200-SMA.
  • The stock sits on a confluence zone of 166.93–171.02: the 200-SMA, the lower Bollinger band and two matching intraday lows.
  • Weekly z-score is −0.38 and ATR is contracting from 9.12 to 7.06. The selling is orderly, not capitulating.
  • QCOM has shown it can re-rate fast. It went from 122.94 to 248.74 in under two months, and from the 7/31 low of 146.81 to 201.97 by 9/25 (+37.6%). It also has a pattern of higher lows (122.94 → 146.81 → mid-150s in August).

A 14.5% pullback from a September high is ordinary for a stock with a 1.65 beta and ATR around 4%.

6. Sentiment and macro are priced in

The headlines are skeptical: "capital leaving," "AI rebrand refuted," handset concentration. When a company wins its biggest legal fight and the stock falls anyway, expectations are already low. Meanwhile, QCOM showed relative strength on at least one down-market day, and a 500-contract $182.5 call sweep suggests someone is positioned for a bounce.

On macro, hot CPI and 97% odds of no 2026 cuts are real headwinds, but they are consensus. Polymarket puts recession odds at just 8%, so this is a rates-multiple problem, not a demand collapse. A 17x forward multiple with a dividend and buyback is better positioned for it than the high-multiple AI names those "bubble" warnings target.

7. Insider selling is noise

Insider sales totaled $20.2M over 12 months, about 0.01% of shares outstanding. The COO sells in fixed monthly lots, and the CEO sells at round-number limit prices, which looks like plan-based selling. I wouldn't weight it.

Where I could be wrong

I'm not asking you to ignore the risks. These would weaken my thesis:

  • A decisive close below about $167–168, which breaks the confluence zone and opens the August range near $155–160.
  • Q4 results or FY27 guidance showing opex still outrunning revenue, with operating margin below 16%.
  • Q3's weak operating cash flow turning out to be structural in the 10-Q.
  • Arm appeals or post-trial motions that erode the verdict.

Earnings are likely in early November (to be verified), so these questions get answered within weeks. At 16.9x forward earnings with a 5%+ FCF yield, I'm being paid to wait for those answers.

So, bear: which do you say is the real problem, the margin squeeze or the cash flow? And do you think either one justifies a multiple below 17x? Bull Analyst: # Bull Rebuttal for QCOM: I'll Give You the Facts, but the Frame Is Wrong

I'll answer your closing question at the end. First, here is where you're right.

What I concede

  • The call sweep is a lottery ticket. It's $77,500 of premium on a strike that needs +5.7% in two sessions. I'm dropping it.
  • 4.0% is a legitimate floor-case FCF yield. If Q4 FCF matches Q3's ~$0.5B, TTM FCF falls to ~$7.3B. I'll carry 4.0–5.0%, not 5.6%.
  • PEG 0.79 is my weakest number. It rests on growth the reported operating income doesn't show. I'm dropping it.
  • "Gross margin intact" was too strong. It has slipped ~0.7pt a quarter. It's holding above 53%, but it isn't flat.
  • The verdict is not a P&L event. It hasn't changed the revenue line.
  • Q3 EPS had help from below the line. Net income was 123% of operating income. I'll anchor on operating income and FCF, not EPS.
  • The slide started in Q1. Opex grew ~12% against +5% revenue, so margins were falling before revenue turned.

1. Revenue isn't the root: the dollar bridge

Q3 operating income fell $1,136M year over year. My arithmetic from the table:

Driver Impact Share
Opex growth (+$654M) −$654M 58%
Gross margin rate (55.6% → 53.1%) −$250M 22%
Lower revenue volume −$232M 20%

In margin points, opex is about three-quarters of the 10.3-point compression. In dollars, revenue explains a fifth of the damage. Two more points:

  • Revenue growth went +5.0%, −3.5%, −4.0%. Of that swing, 8.5 points came between Q1 and Q2, and only 0.5 points between Q2 and Q3. The decline has stopped accelerating.
  • I never blamed macro for revenue. My macro point was about the multiple. I agree the revenue problem is company-specific, and I can't size handset concentration or the Apple modem from this data either.

On seasonality, a nine-month vs. nine-month comparison cancels it. Your real point is that Q1 masks the trend, and I accept that.

2. The "36% growth" compares a trough quarter to a number of unknown basis

  • Q3 is the seasonal low. TTM revenue of $44.07B less nine-month FY26 revenue of $32.80B puts Q4 FY25 at ~$11.27B (derived). That is 8.7% above Q3 FY25 and ties to FY25 revenue of ~$44.3B. Annualizing the trough quarter understates the run-rate.
  • You can't have it both ways on forward EPS. You say the basis is unspecified, then treat it as GAAP to get a 36% gap. QCOM's own non-GAAP has historically stripped out stock comp. That is my general knowledge, not in the tools, but it means some of your gap may be definitional.

Here is a scenario, not a forecast. Take Q4 revenue at −4% on the derived comp (~$10.8B) and gross margin at 53%. With opex flat at $3.65B, operating income is ~$2.1B, a ~19% margin. With opex up 5% sequentially, it's ~$1.9B, about 18%. Q3 was $1.63B and 16.3%. The seasonal rebound alone lifts margin, with no cost cuts.

I can't show you a path to $10.20 from this data and won't pretend to. My thesis is that Q3 is the margin trough, and the print will test that.

3. Opex isn't a contradiction

"Cuttable" and "justified" apply to different pieces of the budget. Oryon spending is more defensible after the verdict. A 7.7% sequential jump in one quarter (+2.2% in Q2, then +7.7% in Q3) needs explaining, and the tool doesn't say whether one-time items are in it. I don't need cuts. I need opex growth below revenue growth. I have no evidence of discipline in hand, only evidence that opex is the largest and most controllable part of the problem.

4. Cash and balance sheet: two cherry-picks and an asymmetry

  • OCF isn't a three-quarter slide. Year-over-year OCF was +8%, −4%, −66%. Q2's −18% FCF was mostly the capex step-up (+$319M), which is a choice. The break is Q3. After a −66% quarter I won't call it nothing, but it's one break, not a trend.
  • "Cash down 37%" measures from the December peak. From September it's −18%. Current assets, which include marketable securities that aren't in the cash line, fell only 6.5% since December ($24.6B → $23.0B).
  • The current liabilities jump looks like a reclassification. They rose $1.65B in Q3 while total liabilities were flat ($29.86B → $29.71B). That is an inference, and the 10-Q will confirm. A maturing note is still a claim on cash, but it sits inside a 2.0x current ratio and 0.55x D/E.
  • Roll-off cuts both ways. You apply it to FCF yield. The same print drops the implied −$3.1B Q4 FY25 quarter from TTM EPS. I don't want that optical gain either, since Q2's $7.4B item stays in TTM. That is why I anchor on operating income and FCF.
  • Your own falsifier is close to the base case. You'd soften if OCF returns above ~$3B. Year-ago Q4 FCF was ~$3.4B (derived), so OCF cleared $3B then. Q3 broke the pattern, so it's no guarantee, but we'll know in weeks.
  • Returns exceed FCF. I agree: $10.05B of financing outflow against $6.83B of FCF. The financing line isn't itemized and includes any net debt repayment. The dividend (~$3.8B a year) is 37–42% of FCF, and the buyback is discretionary.

5. The tape: your control group is missing

The verdict date isn't established in the data. Assuming 10/13, QCOM closed +1.4% (176.86 vs. 174.43) on 12.3M shares against 6.9–9.6M the prior days. A Zacks headline has QCOM rising as the market dipped. The fade came on 10/14 (−2.4%), and the 10/14 bar may still be incomplete.

At a 1.65 beta, a ~1.5% index drop on a hot-CPI, chip-selloff day explains that move. I don't have the 10/14 index move, so I'm not asserting that. But you're reading one day's price as a verdict on the verdict with no market control. Your "Arm won other claims" also comes from truncated retail posts, which is weaker evidence than the press-release headline.

6. Technicals: your stop point lands, my zone still matters

  • Your stop point is fair. 167–168 is inside one ATR. I treat it as a weekly-close review level, and position size is the risk control for a 4% ATR name.
  • The zone is three independent measures. The 61.8% retracement of 146.81 → 201.97 is ~167.9. The 200-SMA is 168.04, and the lower Bollinger band is 166.93. Fibonacci is a soft heuristic, but the SMA and band are mechanical.
  • Reward/risk is moderate, not fat. Downside to the 2×ATR zone (~158.5) is −8.2%. Upside to the daily SuperTrend flip (194.48) is +12.7%, or ~1.5:1. Upside to the 9/25 high is +17%, or ~2:1.
  • This is counter-trend. Weekly and daily SuperTrend are DOWN, and MACD is bearish. I'm buying before confirmation, so initial size should be small.

Your three tests

  1. Opex both cuttable and justified. No contradiction, and I don't need cuts, only growth below revenue's. I have no proof yet. The print is the proof.
  2. Revenue turning. I'm not claiming a turn. I'm claiming the −3.5% and −4.0% declines have stabilized and that Q4 benefits from seasonality.
  3. 36% EPS growth. I reject the framing. It compares a trough quarter ×4 to a number of unknown basis. I'll size for the possibility that forward EPS is too high.

How I'd express it, and what proves me wrong

  • Starter position of about a third in the 167–172 zone. Gap risk is two-sided and ~10% (⅖ and 7/30 were gap-downs), so I wouldn't go full size before the print.
  • Adding the rest requires your falsifiers: opex growth below revenue growth, and OCF back above ~$3B.
  • I'm wrong on: a weekly close below ~167, guidance showing opex outrunning revenue again, or a 10-Q showing Q3's cash weakness is structural.

My question back

Your cash-flow case needs Q4 OCF to stay under $3B. What in the data supports that, given flat total liabilities, modest investing outflow and a year-ago Q4 near $3.4B of FCF? You also said not to lean on one quarter, and Q3 is the one that broke the pattern. Bull Analyst: # Bull Closing on QCOM: Fair on the Trough, Not Cheap, and the Recovery Has a Test Date

Your two questions get straight answers first.

1. Your questions

If the print lands on my scenario (~19% margin, ~22x clean EPS), is QCOM cheap?

No. At ~22x FY26 clean EPS it's fairly priced, and I'm retiring "cheap" as my headline, along with the PEG.

Two notes on the 22x. First, your 89–90% net-to-operating conversion uses the three lowest ratios. Q3 FY25 was 96.5%, so 21–22x is the honest range. That doesn't change my answer.

Second, 22x GAAP and 16.9x forward reconcile if the forward $10.20 is non-GAAP with a typical stock-comp add-back. That would make the 36% growth gap mostly definitional. I can't verify the basis, so I value on GAAP and treat SBC as a cost.

Not cheap is also not overvalued. On your own ~$7.8 EPS:

Multiple Implied price vs. $172.62
20x $156 −10%
22x $172 0%
24x $187 +8%

That is a symmetric payoff around today's price, not a short. You have shown the stock isn't a bargain, and I agree. My claim is narrower. It's a fair-priced, sound-balance-sheet company at an earnings trough, with a testable path to $9+ if opex normalizes. At today's cost base, FY27 operating income lands around $8.6B (flat revenue, 53% gross margin, opex at $14.6B), which is below FY26. If opex returns toward Q1's $3.3B a quarter, that becomes ~$9.9B and roughly 20x. Neither case gets to $10.15 without revenue growth. I'm not claiming it.

What does the third buy now that waiting doesn't?

Price, not information. You're right that the print is the same event either way, so I'm cutting the starter from a third to a quarter of target size.

The price is better than it was three weeks ago, though. QCOM is 14.5% below its 9/25 close, and the fundamentals report says nothing new has been filed in seven days. The only company-specific event, the Arm verdict, was positive. The move came from CPI, yields and a memory-chip selloff. On unchanged forward EPS, the multiple compressed from about 19.8x ($201.97) to 16.9x. That assumes consensus didn't move, which I can't verify. Waiting buys information at the cost of that discount. I accept that cost.

2. Where your latest round lands

Opex test. Your arithmetic is right. With revenue at −4% year over year, "opex growth below revenue growth" means opex falls in dollars, and that's a cut. My wording was loose, so I'll state the test I can defend, which is a weaker one:

  • Stabilization test: Q4 opex ≤ $3.65B (no further step-up), and operating margin ≥ 18%.
  • Recovery test: FY27 opex ≤ revenue growth. I agree that one needs a cut or a revenue turn.

Stabilization is the first gate and recovery is the full thesis. The Q4 mechanics make the first gate fair. Revenue of ~$10.8B (−4% on the derived $11.27B comp) is +8.8% sequentially. Flat opex alone takes the opex ratio from 36.7% to 33.7% and margin from 16.3% to ~19%. That's arithmetic, not forecasting. The uncertainty is whether opex is flat.

Q1 as an outlier. Your 13.5% vs. 5.9% sequential comparison is fair, but it cuts both ways. If Q1 pulled demand forward, the Q2/Q3 declines include payback. The nine-month −0.7% nets that out, and −4% overstates the trend. If Q1 was a one-off, your read wins. The data can't distinguish them, but Q4 can:

  • Q4 at −2% or better: the nine-month read is right.
  • Q4 at −4% or worse: yours is.

Cash. I'll take your base case of $8.3–8.7B FY26 FCF, a ~4.5–4.7% yield and down about a third. My $3B OCF bar was the top of your range, so I'll treat ≥ $2.5B plus a timing-consistent 10-Q explanation as a pass and ≤ $2.0B as a fail. I'm setting that after seeing your table.

Three points remain:

  • Dividend cover. The ~$3.8B dividend is covered about 2.2x even in your base case. The dividend is the commitment, and the buyback is the lever. A slower buyback means a smaller share-count benefit, not stress.
  • Current liabilities. They rose $1.65B in Q3 while total liabilities fell $0.15B. That fits a maturing note moving from non-current to current. A $1.65B maturity against $23B of current assets and ~$8.5B of annual FCF is a refinancing decision, not a liquidity event.
  • Cash flow statements. They don't reconcile to balance-sheet cash by ~$2.3B. "Distributions funded by cash drawdown" is directionally plausible but built on statements that don't tie out.

Rates. The deepest Fed market is 97% for no cuts in 2026, and it moved only 1.1 points in a week. The "86% for another hike" shift is in a $0.76M market that the report itself calls noise-prone. A hawkish regime is real, but I wouldn't call the repricing quantified.

Technicals. I'll concede that the Bollinger band, 200-SMA and Fibonacci level are all functions of one price series, so the zone is one reference, not three confirmations. 171.02 has been tested twice, and 167 is a review level whose risk control is position size.

3. Where I still disagree

Your mind-changers are all post-print confirmations. Opex down in dollars, OCF ≥ $3B, a stated EPS basis, positive ex-seasonal growth: by the time all four are in, the stock will have repriced. That's a legitimate way to invest, but it isn't a price view. You haven't said at what price, or on what EPS, you'd own QCOM. Your $7.50 run-rate at 17x gives $127, which you said isn't a target. So what is the bear's fair value, and what would the print have to show for you to act on it?

"Not cheap" isn't "avoid." With a ~2% dividend, a decent chance of a Q4 margin inflection, and a symmetric multiple band, a small position is a defensible bet. It isn't a high-conviction one.

4. Scoreboard

Conceded: - The call sweep, PEG, "cheap," and "gross margin intact." - 4.0–4.7% as the FCF yield range. - The 36% growth gap is real on a GAAP basis. - The pre-print starter has no informational edge. - The opex test I wrote required a cut.

Still holding: - Opex, not the franchise, is the largest dollar driver (58% of the operating income decline). - Q4 seasonality mechanically helps margin if opex is flat. - The balance sheet and dividend are sound. - Waiting trades a 14.5% discount for information.

What proves me wrong: - A weekly close below ~167. - Q4 opex above $3.65B, or operating margin below 18%. - Q4 revenue at −4% or worse, which supports your reading of the trend. - OCF at or below $2.0B with a structural explanation in the 10-Q. - Arm appeals that erode the verdict.

The earnings date is still unverified, though early November is the historical pattern. A small starter in the 167–172 zone, with the rest of the position decided after the print, is the most I can defend today. Bull Analyst: # Bull Closing on QCOM: Fair Price, Small Position, Pre-Committed Tests

Your table is a better frame than mine, so I'll use it. I checked the arithmetic (for example, $8.6B × 90–96.5% ÷ 1.06B = $7.30–7.83) and it holds. A 50/50 weighting gives about $171 against $172.62. I agree the stock is priced as a coin flip.

1. What your table says about the two outcomes

Using my Q4 scenario ($1.9–2.1B), FY26 operating income lands around $9.3B on roughly $43.6B of revenue. Both rows are then measured against the same base:

FY27 case Op income vs. FY26E Op margin
Today's cost base ~$8.6B about −7% ~19.7%
Opex back toward Q1 ~$9.9B about +6–7% ~22.7%
Reference: 9M FY26 actual 22.3%

The gap between the rows is not "trough versus recovery." It is operating income down about 7% against up about 7%. The bullish row only asks the company to repeat the margin it already earned over nine months this year, Q3 included. The bearish row needs margin to keep deteriorating from here. That is a narrow range, and the price sits in the middle of it.

2. The probability question, honestly

On your table the break-even is a row-2 probability of about 57%. The midpoints are +6.0% ($183) and −7.9% ($159). At 50/50 the expected value is about −1%. I can't prove I'm above 57%.

Here is what makes me modestly above even, and I'm calling it judgment, not data:

  • Opex moves in steps, not a smooth slope. FY25 opex was flat at about $2.92–3.00B a quarter. FY26 ran $3.32B, $3.39B, then $3.65B, so sequential growth was +2.2% and then +7.7%. Part of the +12%, +16%, +22% year-over-year "acceleration" is a flat base. Whether Q3 is a step that plateaus or the start of a new slope is not in the data. You read it as revealed priority. I read it as unproven in either direction.
  • The licensing tail is thinner. The verdict isn't a P&L event, as I conceded. It does reduce the chance that a license dispute disrupts the Oryon roadmap. I can't size that, and appeal status is unverified.
  • The balance sheet limits the damage from a bad outcome. Dividend cover is about 2.2x and D/E is 0.55x. This doesn't help the price in a bad quarter, but it is why I'd hold a small position through one.

3. What I'm conceding at the close

  • The 14.5% "discount" is retired. It is measured from a spike. At $172.62 the stock is near its 50-SMA and about 2.7% above its 200-SMA, so it sits near its recent average. Valuation, not the drawdown, is the anchor.
  • The 16.9x is out of my case. The forward EPS basis is unresolved. On GAAP, the multiple is 22–24x on the stabilization case.
  • My stabilization gate equals your top row. Flat opex is today's cost base. Passing that gate means "not worse," not "recovery."
  • The 167 review level does nothing in a gap. Size is the only risk control.
  • My −4% Q4 revenue assumption was conservative, not a forecast. If revenue prints there, you win that test, and I listed it as a falsifier before you did.

4. Where I still disagree

The 20–22x band is an assumption, and it drives the result. A one-turn shift moves the 50/50 value by about $8, roughly 5%. "Fair" is therefore a statement within the model's error. That supports "not a short," and it equally fails to prove "zero edge."

The band probably also isn't independent of the rows. A margin recovery tends to earn a higher multiple and further erosion a lower one. That widens both tails, which is why I'm sizing small. It doesn't hand me an edge.

Your waiting prices are consistent, and I'm choosing a different trade-off. The mid-$150s is about 10% below today, roughly one earnings gap. You get it mostly if the print disappoints. You get row-2 confirmation at a higher price if it doesn't. That is paying for information, and it is rational. My choice is to hold a small position now so I'm not fully out if the print gaps up. I accept that this has no proven edge and some variance cost. It is a modest-conviction decision, and it is allowed to be small.

5. Final position

Position: A quarter of target size, in the 167–172 zone. Confirm the earnings date first, since early November is historical and unverified. Don't add before the print.

Add the rest only if the print shows: - Q4 opex around $3.4B or below, with FY27 guidance that holds it there. - OCF at or above $2.5B, with a 10-Q that explains Q3. - Q4 revenue at or better than −2% year over year. - A stated basis for the $10.20.

I accept your four conditions as my add criteria.

I'm wrong, and I cut or stop adding, if: - Q4 opex comes in above $3.65B, or operating margin below 18%. - Q4 revenue comes in at −4% or worse. - OCF is at or below $2.0B with a structural explanation in the 10-Q. - A weekly close comes in below about 167. - Arm's appeal or post-trial motions erode the verdict.

Bottom line

You showed the stock is fairly priced, and I agree. You haven't shown it is broken. This is a sound balance sheet, a covered dividend, and a business whose own nine-month margin sits above the bear's lower row. The price already reflects both outcomes. That supports a small position and strict follow-through on the tests above, not a high-conviction buy. Bull Analyst: # Bull Final Reply on QCOM: Revenue Was the Missing Variable, and It Moves My Entry Price

I rechecked your −4% table with your inputs. $43.6B × 0.96 × 0.53 − $14.6B gives ~$7.6B, and each 1% of revenue is ~$230M of operating income, or ~$0.20 of EPS. Your numbers hold, and they change my position.

1. Where you're right

  • My table assumed flat revenue. Revenue was the biggest unmodeled variable, and I left it out of both rows.
  • My Q4 scenario sits on my own cut trigger. The last two prints were −3.5% and −4.0%, so −4% is the trend, not a conservative case. My base case and my stop coincided.
  • The 167 weekly-close level is inside one ATR (4.1%). As a cut rule it would likely fire before the print tells me anything.
  • The rules were asymmetric and left a hole. Four conditions to add, any one of five to cut, and nothing for the modal outcome.
  • Row 1 is Q3 held flat, not deterioration. The 22.3% nine-month margin was also weighted by Q1's record quarter.

2. Where the data doesn't support your framing

"Zero observations of a plateau." FY25 opex ran $2,953M, $2,922M and $2,997M, three quarters within 2.6%. The record is flat-then-step, and whether FY26 is the second step is unproven. But "zero plateau observations" isn't in the data.

The size of the cut. Row 2 is a 9% cut only against annualized Q3. Against FY26 spending (~$14.0B if Q4 matches Q3), $13.2B is about −6%, or ~$0.8B. It's still a cut, and I agree on that. The first thing to read in the release is the Q3 step of $261M ($3,390M to $3,651M). The report says it doesn't know whether one-time items sit in that line. If most of the step is non-recurring, opex reverts to ~$3.4B with no discretionary cut. I'm not asserting that, only that the print is the first place to check.

Your status quo is applied unevenly. You hold costs at the Q3 level, which is status quo. But you carry revenue at −4% again, which is another leg down. YoY declines fade mechanically if the level stabilizes. The consistent version is:

  • Q2–Q4 held at FY26 dollar levels, so YoY goes to ~0.
  • Q1 reverting from the record toward FY25's ~$11.7B. That is your own "Q1 is an outlier" argument.

That gives ~$43.0B, or −1.3%.

3. The table with revenue in it

Same inputs as yours: 20–22x, 90–96.5% conversion, 1.06B shares. The rest is my arithmetic.

FY27 revenue Row 1 ($14.6B opex) Row 2 ($13.2B opex) 50/50 value
Flat ($43.6B) $146–172 $168–198 ~$171
−1.3% ($43.0B) $139–164 $163–192 ~$165
−4% (yours) $129–152 $152–180 ~$153

Equal-weighting the three revenue cases gives ~$163, about 5–6% below $172.62. At my status-quo revenue, row 2 needs about a 79% probability to break even on this band, or ~62% if the multiple moves with the row. I can document neither.

I'm withdrawing the starter at market. Buying at $172.62 pays a premium to my own central value. Its only purpose was to avoid being fully out on a gap up, and that is a hedge against regret, not an edge. You called that variance without edge, and I accept it.

4. Revised rules

  • Entry: A quarter-size starter only on a limit at or below ~$165. That is my 50/50 value at status-quo revenue, ~21x on $7.8. Your entry is the mid-$150s, ~20x on the same EPS. We now differ by about one turn of multiple, which is inside the model's error.
  • Risk control: Position size, not a stop inside one ATR. I'm dropping the 167 weekly-close cut.
  • After the print: My Q4 central case is revenue around −3.5%, which fails the revenue test below. So the base case is "no add" unless opex surprises.
Q4 result Action
Opex ≤ ~$3.4B and revenue ≥ −2% and OCF ≥ $2.5B with a benign 10-Q Build toward full size
Opex ≥ ~$3.65B and revenue ≤ −4% Exit any starter
Anything mixed Hold size, no add, revisit at FY27 guidance or the 10-K

I'd also want a stated basis for the $10.20 before sizing past a starter. Confirm the earnings date first. "Early November" is the historical pattern and is not verified.

5. What survives of the bull case

  • Opex is the discretionary 58% of the dollar damage. Whether the Q3 step recurs is the single most valuable fact in the print.
  • Seasonality lifts Q4 margin mechanically. At flat opex it goes from 16.3% to ~19%. You're right that this doesn't prove recovery, but it also isn't a collapse.
  • The balance sheet is not the problem. The dividend is covered ~2.2x and D/E is 0.55x. The buyback is the flex.
  • The Arm verdict is optionality, not earnings. It lowers the chance that a license dispute disrupts the roadmap, but I can't size it.
  • Price discipline is the edge. At $165 or lower, the stock prices in the stagnation row. At $172.62 it doesn't.

6. Where we stand

Agreed: - QCOM is fairly priced to modestly rich and is not a short. - The decisive tests come at the print: Q4 opex, revenue and OCF. - The $10.20 forward EPS basis is unbridged. - FCF is down roughly a third in the base case, and distributions exceed it.

Still different: - My entry is ~$165 and yours is the mid-$150s. - You read the Q3 opex step as a revealed priority. I read it as unresolved until the release shows what's in it.

The bull case here is conditional. Own QCOM if the print shows opex normalizing, or if the market offers a price that already assumes it won't. It isn't a case for paying $172.62 on faith.

Bear Researcher

Bear Analyst: # Bear Case for QCOM: Cheap on a Forecast, Expensive on the Facts

You asked whether the real problem is the margin squeeze or the cash flow. I say neither, because they are one problem seen on two statements: spending is growing faster while revenue shrinks. Cash flow shows it first because it has no accounting cushions.

1. Revenue is the root, and macro doesn't explain it

Revenue growth went from +5.0% to −3.5% to −4.0% over three quarters, a 9-point swing. Your "nine months is only −0.7%" leans on Q1, the seasonal peak (Q1 > Q2 > Q3 in both fiscal years). Compare like for like and Q3 shows:

  • Revenue −4.0%
  • Gross profit dollars −8.4%
  • Operating income −41%
  • EPS −23%
  • FCF −81%

You also told me recession odds are 8% and this is "a rates-multiple problem, not a demand collapse." If so, macro isn't what's shrinking QCOM's revenue. The cause is company-specific. The news report flags handset concentration and Apple-modem exposure as the items to check, and I can't size either from this data. But you can't blame the tape for a revenue decline when your own recession number is 8%.

Your Q1 argument also cuts against you. At record revenue, up 5%, operating margin was 27.5% against 30.5% a year earlier. Margin was already sliding when the top line was at its best.

2. The 17x is a multiple of an EPS that doesn't exist yet

Forward EPS is $10.20. TTM EPS is $8.64 and distorted. The Q3 run-rate is about $7.50. Getting to $10.20 takes about 36% growth over the current run-rate, and the report says the basis (GAAP or non-GAAP) is unspecified. The PEG of 0.79 implies roughly 21–25% annual growth if computed conventionally. The actual operating income trend is −5%, −26%, then −41%.

You conceded that the latest quarter annualized gives about 23x. At 17x on that run-rate, the stock would be about $127. That isn't a price target. It shows that the "cheapness" is a forecast, not a fact. EV/EBITDA is around 16x, which the report calls an upper bound, for a business with falling revenue.

3. Your opex argument contradicts itself

You say opex is "a lever management controls," so margins will recover with discipline. You also say that if the Arm win makes the custom-silicon bet defensible, "the spend looks better." You can't have both.

If the spend is bloat, management has pulled the lever the wrong way for three straight quarters. Opex growth went +12%, +16%, +22% while revenue turned negative. If it's strategic investment in Oryon, PCs, auto and AI, it won't be cut, and your cost-discipline recovery doesn't happen. Capex doubled for the same reason. Either way, the margin recovery you're waiting for needs revenue growth, and revenue is going the other way.

Gross margin isn't "intact" either. It fell three quarters in a row (54.6%, 53.8%, 53.1%).

4. Cash flow is a trend, not a quarter

You called Q3 a "one-quarter anomaly." FCF year over year was +2.5%, −18.1%, then −80.8%. Q2 and Q3 combined are $2.4B against $4.9B a year earlier, down 51%.

  • The 5.6% FCF yield uses a stale quarter. TTM FCF of $10.24B includes a roughly $3.4B Q4 FY25 that rolls off with the next print. If Q4 FY26 looks like Q3 (about $0.5B), TTM FCF falls to about $7.3B and the yield to about 4.0%.
  • Returns exceed FCF. Nine-month financing outflow was $10.05B against FCF of $6.83B. Cash is down 37% since December, and the current ratio went from 2.82 to 2.02.
  • The buyback is being funded by the balance sheet. You count the 2.4% share shrink as a pillar. At this FCF it either slows or the balance sheet pays for it. Add the unconfirmed Ambarella chatter and capex running double, and the claims on cash are growing while cash generation shrinks.
  • The data has its own gap. The cash flow statements don't reconcile to balance-sheet cash by about $2.3B. Your FCF math comes from those statements.

I agree it's not distress. But "not distress" is a low bar for a stock that needs to hold a premium multiple.

5. The market has already judged the Arm verdict

The tape is the evidence here. On 10/13, QCOM closed at 176.86 after a 180.78 intraday high, and it fully faded. Today's close of 172.62 is below the 10/12 close of 174.43, the day before the reaction window, assuming the verdict landed on 10/13 as the sentiment feed implies. A win that can't hold a bounce means buyers aren't treating it as material.

You say "expectations are already low." The simpler read is that the verdict doesn't touch the P&L problem. Damages were $2, Arm reportedly won other claims, the royalty-suspension question is open, and you concede appeal status is unverified. "License certainty" with an appeal pending isn't certainty. And with the Oryon roadmap now "de-risked," revenue still fell 4%.

6. Your own invalidation level sits inside the noise

You say you'd be wrong below $167–168. That's 2.7–3.3% below today's price. ATR is 4.1%. Your stop is inside one average day's range.

  • "Orderly, not capitulating" is not bullish. RSI is 42.36, far from oversold. MACD has made 13 straight lower readings. OBV peaked on 9/17 before price did. No washout means the sellers may not be done.
  • The pullback has retraced 53% of the 7/31–9/25 rally.
  • The monthly SuperTrend is UP with a stop 48% below price. It's useless for risk. The weekly flips only at 223.47, about 29.5% higher.
  • The re-rating cuts both ways. QCOM went from 248.74 to 146.81 in two months, −41%, and gapped down 10.7% on ⅖.
  • The 171.02 low has been tested twice. It's the 10/8 low and today's low, and today's close is 0.9% above it.

7. "Priced in" isn't what the prediction markets show

The Polymarket numbers are moving, not settled. Odds of another hike in 2026 rose 8 points in a week to 86%, and "exactly 3 hikes" gained about 10 points. Add global bond yields surging, mortgage rates at three-year highs and oil near $103, and this is a hawkish repricing in progress. QCOM has a 1.65 beta. A 2.08% dividend doesn't hold up a stock in that regime. I can't quote the 10-year (FRED failed), but the headlines say it's rising.

On "being paid to wait": the quarterly dividend is $0.92, or 0.53% of the price. The average daily range is $7.06, about 7.7 times the quarterly payout. On the prior pattern, the next ex-date is early December, after earnings.

8. Quick hits

  • The call sweep is 500 contracts, about $77,500 of premium. The $182.5 strike now needs a 5.7% rally in two sessions. That is a lottery ticket, not conviction.
  • Insiders: I agree the sales are small. The point is that the 150-row record shows zero open-market purchases across a $122–$260 range, including the April and July lows. The CEO also sold 150,000 shares for $24.8M at about $165–167 in October 2025, roughly today's price.
  • Q3 EPS was cushioned. Net income was 123% of operating income, against 97% a year earlier. The −23% EPS decline flatters the −41% operating decline.

What would change my mind

  • Q4 or FY27 guidance showing opex growth below revenue growth.
  • Operating cash flow back above about $3B.
  • Revenue growth turning positive without Q1 seasonality.
  • A clean 10-Q explanation of the current liability jump.

None of that is in the data today, and the earnings gap risk (early November, unverified) comes first.

So here is my question back. Your thesis needs opex to be both cuttable and justified, revenue to turn, and EPS to grow 36%. Which of those three do you have evidence for today, beyond the multiple on the screen? Bear Analyst: # Bear Rebuttal for QCOM: Your Falsifier Needs a Cut, and Your Best Case Still Isn't Cheap

You asked me a direct question, so I'll answer it first. Then I'll show where your own numbers lead.

1. Your question: what supports Q4 OCF staying under $3B?

Nothing in the data forces it, and I don't need a point forecast. The ~$3.4B year-ago Q4 FCF is a real comp, and a timing reversal is possible. What the data does allow is a test of $3B against your own Q4 scenario (operating income of $1.9–2.1B), using cash conversion (OCF ÷ operating income) from the filings:

Conversion basis Ratio Implied Q4 OCF
9M FY25 106% $2.0–2.2B
9M FY26 115% $2.2–2.4B
Q1 FY26 (best quarter in the dataset) 147% $2.8–3.1B

These are my arithmetic from the tables. If Q3's shortfall (~$0.6–0.7B below normal conversion) fully reverses and sits on top of FY25 conversion, you get roughly $2.6–2.9B. So $3B needs the best conversion quarter on record or operating income above your scenario. It is the top of the range, not the center.

Two concessions: - Cash flow is not a separate trend. Over nine months OCF fell 16% against operating income's 23%. That is my opening point: one problem, not two. The part that isn't operating income is capex, which doubled and accounts for $0.79B of the $2.40B nine-month FCF decline. That is spending too. - The 10/13 tape is too thin to use. I have no index control for it. Please drop the Zacks headline as evidence of relative strength as well.

The yield barely moves the debate: - Base case (OCF $2.0–2.4B, capex ~$0.5B): FY26 FCF is about $8.3–8.7B, a ~4.5–4.7% yield and down 31–34% from FY25's ~$12.6B (derived). - Your $3B case: FCF is about $9.3B, a ~5.0% yield, still down ~26%.

Even if you win this point, FCF is shrinking by a quarter or more. Financing outflow is already $10.05B through nine months, above full-year FCF in either case. You agreed the buyback is discretionary, and that is the pillar behind your 2.4% share shrink.

Flat total liabilities tells you where the cash didn't go. It doesn't tell you the cash comes back. Net working capital (current assets minus current liabilities) is down $3.2B, or 22%, since December. If the $1.65B current-liability jump is a maturing note, as you suspect, it draws on the same $4.5B cash balance that distributions are already outrunning.

2. Your own falsifier is arithmetically a cut

You said "I don't need cuts, only opex growth below revenue growth," and "I'm not claiming a turn." Revenue growth is currently −4%. Opex growth below −4% means opex has to fall in dollars year over year, and that is a cut.

On Q3's numbers, opex 4% below the year-ago $2,997M is ~$2.88B, not $3.65B. That is about $770M a quarter, or $3B a year. If you test it on FY27 guidance instead, you've turned it into a revenue-turn test, which you also declined to claim. You can't have no cuts, no turn, and a passing grade on your own test.

On "Q3 is the trough," only one thing has stabilized, and it's the one that was never the main driver: - Revenue growth held at −3.5% and −4.0%. But the seasonal Q2→Q3 drop was −6.2% this year against −5.6% last year, so it's slightly worse. - Opex growth ran +12%, +16%, +22%, and it jumped 7.7% sequentially in a quarter when revenue fell 6.2%. - Operating income ran −5%, −26%, −41%, and gross margin has fallen three quarters in a row. - Your bridge is right that opex is 58% of the dollar damage. But the other 42% (−$482M) is at the gross profit line, which is volume and margin rate. That is the franchise, and you conceded it isn't "intact."

Q1 also looks like an outlier, not a base. It fell 13.5% sequentially into Q2, against 5.9% a year earlier.

3. Your best case still isn't 17x

Take your Q4 scenario at face value: - Nine-month operating income of $7.30B plus Q4 of $1.9–2.1B gives FY26 of about $9.2–9.4B. - In clean quarters net income ran ~89–90% of operating income (Q1 FY25, Q2 FY25 and Q1 FY26). That gives net income of about $8.3–8.5B, or EPS of about $7.7–7.9. - At $172.62 that is ~22x, on your best case. - $10.20 EPS needs about $10.9B of net income, which is about $12.1B of operating income. That is 29–32% above your best-case year.

You wrote "I can't show you a path to $10.20 from this data and won't pretend to." That concedes the valuation leg. The non-GAAP point doesn't rescue it. Without a TTM non-GAAP figure, you can't size the definitional gap, and stock comp is a real cost either way. And 16.9x is a low multiple only because the denominator already assumes a ~30% rebound. In EPS terms, expectations are high.

4. Technicals and the starter position

  • The zone isn't three independent measures. The Fibonacci level, the Bollinger band and the 200-SMA are all functions of the same price series. The band is a moving statistical envelope, not a level where orders rest. 171.02 has also been tested twice in a week.
  • Your risk control is position size only. You moved the 167 level from an invalidation point to a "weekly-close review level." At a 4.1% ATR and 1.65 beta, size is all that's left.
  • The starter buys no information. You'd add only after opex and OCF pass, and both come out in the same event (early November, unverified). You also called gap risk two-sided at ~10%. If the print is a coin flip, the starter has zero expected edge and extra variance. If you think it's better than a coin flip, name the evidence. Your own line says "I have no evidence of discipline in hand."
  • The backdrop leans against you. Weekly and daily SuperTrend are down, MACD has made 13 lower readings, and Polymarket shows 86% odds of another hike and 97% odds of no cuts. That is a rising discount rate on an earnings number at risk.

Where I stand

What you've moved me on: - Opex is the largest dollar driver. - OCF isn't an independent slide. - The single-day tape is weak evidence.

What still holds: 1. Your opex test requires a cut or a revenue turn, and you claim neither. 2. Your best-case Q4 implies about $7.7–7.9 of clean EPS and ~22x, against the $10.20 behind the 16.9x. 3. FY26 FCF is down roughly 26–34% in every scenario, while distributions already exceed it. 4. A pre-print starter takes the gap risk and gains no information.

What would change my mind: Q4 opex falling in dollars with FY27 guidance showing it stays down, OCF at or above $3B with a 10-Q explaining Q3, a stated basis for forward EPS that reconciles to something near $10, and revenue growth positive ex-seasonality.

My question back

If the print lands exactly on your own scenario (a ~19% margin and ~22x clean EPS), do you still call QCOM cheap? And if the falsifiers decide when you add, what does the third you buy now get you that waiting a few weeks doesn't? Bear Analyst: # Bear Closing for QCOM: $172.62 Prices a Coin Flip, and the Trend Favors the Wrong Side

You retired "cheap," the PEG and the call sweep. I'll answer your two questions, then show where your closing numbers point.

1. Your questions

What is the bear's fair value? I used your two FY27 cost cases, about 1.06B shares, your 90–96.5% net-to-operating conversion range, and a 20–22x band:

FY27 cost base Operating income EPS Value at 20–22x P/E at $172.62
Today's (opex ~$14.6B) ~$8.6B $7.3–7.8 $146–172 22–24x
Opex back toward Q1 ($3.3B/qtr) ~$9.9B $8.4–9.0 $168–198 19–21x
What $10.20 requires ~$11.3–12.1B $10.20 n/a 16.9x

The midpoints are about $159 and $183, and their average is about $171. So $172.62 is the price of a 50/50 bet on which cost base shows up. I'm not calling that a bargain or a short. But the only evidence in hand favors the top row: opex growth of +12%, +16% and +22%, and your own line, "I have no evidence of discipline in hand." Neither row gets to 16.9x.

What would the print have to show? Your stabilization gate (Q4 opex ≤ $3.65B, margin ≥ 18%) is the top row by definition, because flat opex is today's cost base. The margin leg is delivered by the calendar. Q4 revenue is +8.8% sequentially on your own derivation, and last year's Q4 had the same calendar. A ~19% margin would still sit 7 points below the weakest FY25 quarter (26.6%). I can't derive Q4 FY25 operating income from this data, so the exact YoY gap is unverified. You could pass your gate and still be holding the stock at the top of its fair range.

I'd move to the second row if I saw: - Q4 opex clearly lower, around $3.4B or below, with FY27 guidance that holds it there. - OCF ≥ $2.5B with a benign 10-Q. That's your bar, and I'll take it. - Q4 revenue ≥ −2% YoY, which is your own test. - A stated basis for the $10.20.

Without that, I'd want the mid-$150s, which is ~20x on $7.8. That is also the August range and the 2×ATR zone near $158.5.

You're right that my falsifiers are post-print. That's deliberate. One event resolves both questions, you've sized gap risk at ~10%, and your own table is symmetric. Paying before the print means paying fair value for the option with the trend against you.

"Not cheap isn't avoid." Agreed on one point: this is not a short. The dividend is covered about 2.2x, D/E is 0.55x, and gaps cut both ways. But a quarter-size starter with a symmetric payoff and, by your admission, no informational edge has zero expected value and only variance. A 10% gap moves a quarter-size position about 2.5% of target in either direction. "Defensible" isn't the same as "has an edge."

2. The "14.5% discount" isn't one

The 14.5% is measured from a 9/25 close that followed a +37.6% rally in under two months. Nothing in our data explains that rally. The fundamentals report shows no new filings in seven days, and the earlier headlines read as narrative-driven. A pullback from a spike isn't a discount. At $172.62 the stock sits near its 50-SMA ($173.98) and 2.7% above its 200-SMA ($168.04), roughly the year's average price. Over that stretch, YoY operating income went from −5% to −26% to −41%. The "19.8x to 16.9x" compression also assumes consensus didn't move, which you've said you can't verify.

3. Narrower points

  • The 16.9x is a dilemma. If the $10.20 is GAAP, it needs far more than your FY27 base case delivers. If it's non-GAAP, it embeds an SBC add-back I can't size. You said you value on GAAP and treat SBC as a cost. On that basis the multiple is 22–24x, not 16.9x.
  • Your Q4 scenario is my revenue case. You model Q4 at −4% and also say −4% or worse supports my reading of the trend. If revenue lands on your base case, I win that test.
  • "Controllable" isn't "controlled." Opex is 58% of the dollar damage, as you showed. But a lever that has been pulled the wrong way for three straight quarters, with a +7.7% sequential jump in Q3, is a demonstrated priority.
  • Your 167 review level can't operate in the event that matters. A weekly-close level can't protect you through a 10% gap. Size is the only control, and you've said so.

4. Scoreboard

Conceded to the bull: - Opex is the largest dollar driver (58%). - OCF is not an independent trend, and the single-day tape is weak evidence. - The balance sheet and dividend are sound, and the current-liability jump is most likely a maturity, not a liquidity event. - The 86% hike market ($0.76M) is noise. The 97% no-cuts market ($8.9M) is not, and it says rates give no relief. - This is not a short.

Still standing: 1. Every scenario prices QCOM at 19–24x earnings, and the 16.9x depends on a number neither of us can bridge. 2. The bull's own gate confirms today's cost base, not a recovery. 3. FY26 FCF is down about a third in the base case, and distributions already exceed it. 4. Operating income, opex and FCF are all still worsening YoY, so the "trough" claim is untested. 5. The starter has no information edge and no price edge.

Bottom line

I'd stay out ahead of the print. At $172.62 QCOM sits between two outcomes, a $146–172 range if opex holds and a $168–198 range if opex reverts, and the trend favors the lower one. I'd revisit after a print that shows the second row, or in the mid-$150s. The earnings date is still unverified, so confirm it before positioning. Bear Analyst: # Bear Final Rebuttal for QCOM: Your Table Assumes Flat Revenue, and Your Base Case Trips Your Own Stop

I rechecked your arithmetic and it holds: ~$171 at 50/50, a 57% break-even, and about −1% expected value. We agree QCOM is fairly priced and not a short. I still don't think a starter earns its variance, for four reasons.

1. The "bearish row" is the status quo, not deterioration

You wrote that the bearish row "needs margin to keep deteriorating." It doesn't. Row 1 is Q3's opex ($3.65B a quarter) held flat for a year, with gross margin at 53% (Q3 was 53.1%). Nothing gets worse. Its 19.7% margin beats Q3's 16.3% only because a full year includes the seasonal peak.

Row 2 is the one that needs something to happen. Opex at $3.3B a quarter is a ~9% cut from Q3, or about $1.4B a year. The largest sequential opex decline in the six quarters we have is about 1% (Q1→Q2 FY25, $2,953M → $2,922M). You agreed earlier that the recovery case needs a cut or a revenue turn, and you've claimed neither.

The "nine-month margin of 22.3%" comparison also misleads. It is weighted by Q1's record $12.25B quarter at 27.5%, while the exit rate is 16.3%.

2. The hidden assumption is flat FY27 revenue

Both rows use ~$43.6B, flat on FY26E, but the last two quarters ran −3.5% and −4.0%. At a 53% gross margin, each 1% of revenue is ~$230M of operating income, or ~$0.20 of EPS. Each point of gross margin is ~$0.38, and it has lost ~0.7 point a quarter for three quarters.

Here is your table with revenue at −4%. Same cost bases, same 90–96.5% conversion and ~1.06B shares, at 20–22x:

FY27 case, revenue −4% Op income EPS Value
Today's cost base ~$7.6B $6.4–6.9 $129–152
Opex back to Q1 ~$9.0B $7.6–8.2 $152–180

Even your good row now has a midpoint of ~$166, below $172.62. The coin flip is only about opex if revenue is flat, and you haven't claimed that. The Q4 revenue line decides which table we're in.

3. Your reasons for being above 57%

You called them judgment, so I'll weigh them as judgment.

  • "Opex moves in steps." Every observed FY26 sequential move is up: +2.2%, +7.7%, and +10.7% across the two quarters from Q3 FY25 to Q1 FY26. There are zero observations of a plateau. "Unproven in either direction" is fair, but the only evidence points one way, and you need more than 50%.
  • "The licensing tail is thinner." You conceded this isn't a P&L event, can't be sized, and has an unverified appeal status. A reason with no number can't move a probability from 50 to 57.
  • "The balance sheet limits the damage." It bounds credit and dividend risk, which nobody here disputes. It doesn't bound a de-rating or a 10% gap.

4. A correlated multiple doesn't rescue the starter

You're right that the multiple probably moves with the row. Take 22–24x for recovery and 18–20x for erosion, with your flat-revenue assumption. The rows become ~$200 and ~$144, and the break-even probability falls to ~51%. That helps you, but the swing widens to roughly ±16%. At 50/50 the expected value is still about zero, so it's a bigger coin flip, and you've named no evidence for tilting it.

5. Your rules, read literally

  • Adding needs all four conditions (opex ≤ ~$3.4B, OCF ≥ $2.5B, revenue ≥ −2%, a stated EPS basis). Cutting needs any one of five.
  • Your Q4 scenario already trips a trigger. It assumes revenue at −4%, and "−4% or worse" is on your cut list. You call that conservative, but the last two prints were −3.5% and −4.0%.
  • The modal outcome has no rule. If opex lands at $3.4–3.65B and revenue at −2% to −4%, neither the add nor the cut rule fires.
  • The 167 trigger sits about one ATR below the price. The likeliest path for the starter is being stopped out before the information arrives, which means you've bought variance, not the option.

Scoreboard

Conceded to the bull: - Opex is the largest dollar driver (58%). - OCF is not an independent trend. - The balance sheet and dividend are sound. - The call sweep, the single-day tape and the 86% hike market are weak evidence. - This is not a short.

Still standing: 1. The bullish row requires a ~9% opex cut with no precedent in the data. 2. The valuation table rests on flat revenue that the last two quarters contradict. 3. FY26 FCF is down roughly a third, and distributions already exceed it. 4. The starter has no price edge, no information edge, and rules that favor getting cut.

Bottom line

I'd stay out ahead of the print. This is a wait, not a short. I'd act on any of these:

  • A print showing row 2: Q4 opex ≤ ~$3.4B with FY27 guidance that holds it there, OCF ≥ $2.5B with a benign 10-Q, Q4 revenue ≥ −2%, and a stated basis for the $10.20.
  • A price in the mid-$150s, which is ~20x on ~$7.8 and the August range.

Confirm the earnings date first, since "early November" is still the historical pattern and not a verified date. Bear Analyst: # Bear Close on QCOM: We Agree on the Tests, but $165 Still Isn't a Discount

I reran your −1.3% table and it holds: $139–164, $163–192, a ~$165 midpoint, and break-evens of about 79% (62% if the multiple moves with the row). Withdrawing the market-price starter is a real move, and I'm not going to pretend it isn't. Below I concede three points, then show where the remaining gap sits.

1. What I concede

  • "Zero plateau observations" overreached. FY25 opex ran $2,953M, $2,922M and $2,997M, within 2.6%. The pattern is flat, then step up. My narrower point stands: the largest sequential decline in the data is about 1%, so a cut has no precedent here.
  • Part of the Q3 $261M step may be non-recurring. The tool can't tell, and I'd read that line first too. But the pre-step quarters already ran +12% and +16% year over year. Row 2's $3.3B a quarter is therefore a return to Q1 FY26's cost base, not FY25's.
  • The table's 1.06B shares don't need a balance-sheet drawdown. In my base case, $8.3–8.7B of FCF less the ~$3.8B dividend leaves roughly $4.5–4.9B. At ~$172 that retires about 2.5% of shares. My cash-return concern is about the nine-month pace ($10.05B of financing outflow), not your table.

2. Your "status-quo" revenue embeds a turn

Your −1.3% case holds Q2–Q4 FY27 at FY26 dollar levels, so year-over-year growth goes to ~0. But Q3 was −4.0%, and a gap doesn't close by itself. Going from −4% to ~0 within two quarters is a 4-point improvement, and you've said you aren't claiming a turn.

The persistence case is simpler. If Q3's gap to the FY25 seasonal pattern just holds, FY27 revenue is the derived FY25 figure of $44.28B × 0.96 ≈ $42.5B. That is −2.5% against your FY26E. I ran it on your inputs (53% gross margin, 90–96.5% conversion, 1.06B shares, 20–22x):

FY27 revenue Row 1 ($14.6B opex) Row 2 ($13.2B opex) 50/50
$43.6B (flat) $146–172 $168–198 ~$171
$43.0B (your −1.3%) $139–164 $163–192 ~$165
$42.5B (Q3 gap persists) $135–159 $158–187 ~$160
$41.9B (−4%) $129–152 $152–180 ~$153

At $42.5B, Row 2's midpoint is ~$173, which is today's price. The market already pays for the full opex-normalization outcome if revenue merely stays on its current trajectory. At $172.62 you pay about 20–22x for Row 2 and 24–26x for Row 1.

The data can't separate "Q1 pulled demand forward and Q2/Q3 are payback" (your flat-to-−1.3% rows) from "Q1 was the outlier and −4% is the trend" (my lower rows). Q4 can. Until then, the only observed evidence is −3.5% and −4.0%, so I weight the central case at $160–165, 4–7% below the price.

3. $165 is not "priced for stagnation"

You wrote that at $165 or lower, the stock prices in the stagnation row. On your own −1.3% table, Row 1 EPS is $6.95–7.46, so $165 is 22–24x stagnation EPS. That is at or above the top of your 20–22x band. You get stagnation at a full multiple and the recovery row as upside, which is fair value, not a cushion.

Your $165 is also your 50/50 value by construction. "Price discipline is the edge" needs a discount to central value, and at central value the expected edge is zero. One turn of multiple is ±$8, so the model can't tell $165 from $172.

My own entry needs the same correction. I derived "mid-$150s" from the flat-revenue $7.8 EPS. On the revenue-consistent rows, $155 is about 21–22x stagnation EPS. Against 50/50 values of $153–171, it offers roughly −1% to +6% of expected edge. That is a modest margin of safety, not a bargain, which is why my stance is "wait," not "accumulate."

4. The recovery row is a lower-margin franchise

At $43.0B, Row 2 gives ~22.3% operating margin and Row 1 gives ~19.0%. The nine-month FY25 margin was 28.6%. Even the bull row is about 6 points below where the company was a year ago, on lower revenue. It is a good outcome relative to Q3's 16.3%, but it isn't a return to the franchise the 16.9x was built on. Gross margin is also assumed to hold at 53% in every row, after three straight quarters of decline. Each point is ~$0.38 of EPS.

5. What's left of the disagreement

Your rule table is better than the last one. Two problems remain:

  • Your own central case fails your add test. You said Q4 revenue around −3.5% misses the ≥ −2% bar. The modal outcome (mixed) means hold, no add. A starter whose base case is "hold and don't add" earns variance and nothing else.
  • Both rules sit under the same event. Late-October FOMC, CPI and the print are all ahead. The 20–22x band was set in a 97%-no-cuts regime with hot CPI and rising yields. I can't quote the 10-year (FRED failed), but nothing in the data suggests multiple expansion. A common factor across both rows skews the band's risk down.

The remaining gap is small: a quarter-size position, about 2.5% of target on a 10% gap, held through a print for no expected edge. I'd rather use the print than hold through it, and that is a sizing judgment, not a valuation fight.

Where we agree

  • QCOM is fairly priced to modestly rich, and not a short. The dividend is covered ~2.2x and D/E is 0.55x.
  • Opex is the largest dollar driver (58%), and the Q3 step is the most valuable line in the release.
  • The $10.20 forward EPS basis is unbridged. On GAAP, the stock trades at 22x or more even in the stabilization case.
  • FY26 FCF is down about a third in the base case, and the OCF ≥ $2.5B pass bar with a benign 10-Q is agreed.

My position

  • No position at $172.62. Confirm the earnings date first. "Early November" is the historical pattern, not a verified date.
  • I'd upgrade after a print showing:
  • Q4 opex ≤ ~$3.4B, with FY27 guidance that holds it there.
  • Q4 revenue ≥ −2% year over year.
  • OCF ≥ $2.5B with a benign 10-Q.
  • A stated basis for the $10.20.
  • I'd also consider a small position in the mid-$150s, with the thin edge described above.
  • I'd get more bearish if opex prints ≥ $3.65B, revenue −4% or worse, and OCF ≤ $2.0B. That puts the −4% Row 1 range of $129–152 in play, 12–25% below the price.

The stock isn't broken, but at $172.62 it is paying for the pass before the test has been taken.

Research Manager

Recommendation: Underweight

Rationale: This debate converged more than most. By the end, both sides agreed on most of the facts, and the bear won almost every contested valuation point. The bull's strongest arguments still stand. Opex, not the franchise, is the largest driver: the bull's own bridge puts 58% of the $1.14B Q3 operating income decline on opex. If opex just stays flat at $3.65B, Q4 seasonality mechanically lifts operating margin from 16.3% to about 19%. The balance sheet is sound (D/E 0.55x, current ratio about 2.0, dividend covered about 2.2x even on base-case FCF). The Arm verdict lowers license risk to the Oryon roadmap, though it can't be sized and appeal status is unverified. Those points are why this isn't a Sell, and both analysts explicitly agreed QCOM is not a short. The bear carried the valuation and trend argument, though, and the bull conceded most of it. The 16.9x forward multiple rests on $10.20 of EPS whose basis is unknown, and nobody could bridge it from the data. On GAAP, even the bull's best Q4 scenario implies about $7.7-7.9 of clean EPS, or about 22x. The fundamental trend is still worsening. Revenue growth went +5.0%, -3.5%, -4.0%. Opex growth went +12%, +16%, +22%. Operating income went -5%, -26%, -41%, and gross margin has fallen three quarters straight. FY26 FCF looks down roughly a third in the base case, while nine-month financing outflow ($10.05B) already exceeds nine-month FCF ($6.83B). The decisive exchange was the bear's point that the bull's valuation table assumed flat revenue. Once revenue goes in, the bull's own status-quo case (-1.3%) gives a 50/50 value of about $165. The persistence case ($42.5B) gives about $160, and there the recovery row's midpoint of about $173 equals today's price. In other words, $172.62 already pays for opex normalization if revenue just holds its trajectory. The bull accepted this, withdrew the market-price starter, and admitted its own central Q4 case (revenue about -3.5%) fails its add test. The technicals don't offer a counterweight. Weekly and daily SuperTrend are down, MACD has made 13 lower readings, and RSI is 42 with no washout. The 171.02 low has been tested twice, and the 167 level sits inside one ATR, so it can't work as a stop. The macro backdrop, with 97% odds of no 2026 cuts and hot CPI, doesn't support multiple expansion. Net, the central value of about $160-165 sits 4-7% below the price, the trend is negative, and a binary print with roughly 10% two-sided gap risk is weeks away. That argues for trimming, not exiting. The edge is real but modest and inside model error (one turn of multiple is about $8), so this is Underweight rather than Sell. Data gaps to flag: the earnings date (early November is the historical pattern, not verified), the GAAP vs. non-GAAP basis of forward EPS, whether one-time items sit in Q3's $261M opex step, Arm appeal status, a roughly $2.3B gap between the cash flow statements and balance-sheet cash, and no 10-year yield data.

Strategic Actions: 1) Confirm the Q4 FY26 earnings date first, and complete all pre-print actions at least one session before it. 2) Trim existing QCOM exposure to about 50% of a standard allocation; do not exit fully, because gap risk is two-sided and the balance sheet and dividend are sound. Sell about half the trim promptly near $172-173, before another test of the 171.02 low. Work the rest with limit orders into any bounce toward $176-181 (the 10/13 high was 180.78), but finish before the print rather than holding out for a bounce. 3) Make no new purchases at current prices; flat accounts stay flat into the print. 4) Control risk through position size, not a tight stop. ATR is about $7 (4.1%), so the 167-168 zone is noise, not an invalidation level. Hold the reduced position through the print, expecting about a 10% gap either way. 5) Pre-print re-entry: only at a real discount to the roughly $160-165 central value. Place resting limit bids in $152-158 (the August range, the 2x ATR zone near $158.5, about 20x on $7.8 EPS) to rebuild toward about 75% of standard, and don't go above that before results. 6) Post-print upgrade path: if Q4 opex is at or below about $3.4B with FY27 guidance holding it there, revenue is -2% YoY or better, OCF is at least $2.5B with a 10-Q explaining Q3's weakness as timing, and the $10.20 forward EPS basis is stated, rebuild to standard weight (100%) in two or three tranches over the following weeks rather than chasing a gap. Reassess for Overweight if FY27 guidance shows revenue turning positive. 7) Post-print downgrade path: if Q4 opex is $3.65B or more and revenue is -4% or worse, especially with OCF at or below $2.0B and a structural explanation in the 10-Q, cut to 25% of standard or exit. The fair range in that case is about $129-152. 8) Mixed outcome (opex $3.4-3.65B, revenue between -2% and -4%): keep the 50% weight, add nothing, and revisit at FY27 guidance or the 10-K. 9) Event watch: an Arm appeal or post-trial motion that erodes the verdict is a reason to trim further. Treat the 500-contract $182.5 call sweep and single-day tape moves as noise. Do not lean on the 2.08% dividend (the $0.92 quarterly payout is about 0.5% of price) to justify holding size through the event.

III. Trading Team Plan

Trader

Action: Sell

Reasoning: The research plan's Underweight maps to a Sell, sized as a trim and not an exit. At 172.62 the price already pays for opex normalization: the status-quo and persistence cases give about $160-165 of central value, and the 16.9x forward multiple rests on a $10.20 EPS basis nobody could verify. The fundamentals are still worsening (revenue growth +5.0%, -3.5%, -4.0%; opex growth +12%, +16%, +22%; gross margin down three quarters), and the technicals confirm it: weekly and daily SuperTrend are DOWN, MACD has made 13 lower readings, RSI is 42.36 with no washout, and today's close is below the 50-SMA (173.98) and 10-EMA (177.99). A binary earnings print with roughly 10% two-sided gap risk is likely late October to early November (date unverified), and the edge is modest, so trim and keep the rest because the balance sheet and dividend are sound. The 171.02 low has been tested twice, so sell about half the trim promptly near 172-173 and work the rest into any bounce toward 176-181, finishing before the print. The 167-168 zone is inside one ATR (7.06), so it is noise and not a stop. The 194.48 daily SuperTrend flip is the level that would invalidate the bearish tilt and prompt a reassessment. Gaps in the evidence: the earnings date, the GAAP vs. non-GAAP basis of forward EPS, Arm appeal status, and the caller's current holdings.

Entry Price: 173.0

Stop Loss: 194.48

Position Sizing: Trim existing QCOM exposure to about 50% of a standard allocation, selling about half the trim near 172-173 and the rest on limit orders into 176-181, finished at least one session before earnings. Flat accounts stay flat. Pre-print, rebuild only with resting bids in the 152-158 area, up to about 75% of standard at most. Post-print, go to 100% only if opex is at or below about $3.4B and revenue is -2% YoY or better. Cut to 25% or exit if opex is $3.65B or more and revenue is -4% or worse.

FINAL TRANSACTION PROPOSAL: SELL

IV. Risk Management Team Decision

Aggressive Analyst

Aggressive Analyst: Neither of you has spoken yet, so I'll make the case and then take on the objections I expect.

The decision is a trim to about half a standard allocation, not an exit. I'd call that disciplined aggression: act on the evidence now, keep half the upside, and hold dry powder for a better price.

The evidence points one way. Revenue growth went +5.0%, then -3.5%, then -4.0%, while implied opex growth went +12%, +16%, +22%. That is the opposite of operating leverage. Operating margin fell from 30.5% to 16.3% in six quarters, and Q3 operating income was down 41%. Q3 free cash flow was $495M, down 81%, with capex doubling. Over nine months, financing outflows of about $10B ran roughly $3.2B ahead of FCF, so cash is falling and the current ratio has gone from 2.82 to 2.02. At $172.62, the stock is paying for a recovery in a cost line that is still moving the wrong way.

The tape agrees. Weekly and daily SuperTrend are both down, MACD has made 13 straight lower readings, and OBV fell with price. Today closed below the 50-SMA and the 10-EMA. RSI is 42, so there's been no washout. The 10/13 bounce topped out at 180.78 and closed at 176.86, then gave back 2.4% today. A stock that can't hold a bounce after a headline legal win is telling you something about who is selling.

Here is how I'd answer the likely pushback.

The conservative analyst will say a 16.9x forward P/E, a 2% dividend that's well covered, and a sound balance sheet make this a hold. I'd agree the dividend is safe at roughly 37 to 42% of FCF, and that's exactly why we trim and don't exit. But the 16.9x rests on $10.20 of forward EPS, and nobody can say whether that's GAAP or non-GAAP. The latest quarter's $1.87 annualizes to about $7.50, or roughly 23x. A 2% yield doesn't compensate you for a 14.5% drawdown in 14 sessions. "Sound" describes the level of the balance sheet, and the direction of cash, liquidity and returns versus FCF is negative.

The conservative will also say selling now means missing a rebound. We keep half the position, so a rip back toward 200 still pays us. If the stock bounces toward 176 to 181, we sell the second half of the trim into that strength at better prices. The plan benefits from a bounce and doesn't need a collapse.

The neutral analyst will say to wait for earnings and decide with real information. But the print is a roughly 10% two-sided gap in a name with a 1.65 beta, and the date isn't verified. We also can't verify the earnings base, because there's a $7.4B Q2 net income distortion and an implied Q4 FY25 loss. Holding full size through that is a bet, not patience. Opex has to turn first, and the burden of proof is on the print. If it's good, we hold 50% and can add back at 100% if opex is at or below about $3.4B and revenue is -2% or better. If it's bad, we've already dodged half the damage. Because the date is uncertain, I'd start executing now and not wait for a bounce that may not come.

The neutral may also say the Arm verdict de-risks the story. It does, strategically, but retail summaries say damages were $2 nominal, Arm won some claims, and the royalty question is open. I can't verify those details from the tools. What I can see is the price reaction, and the market isn't rewarding the win. Good news that fails to lift a stock is a classic distribution tell.

I'll concede some things. The macro read is headline-based because FRED failed, and the 86% "another hike" market is thin at under $1M of volume, though the 97% no-cuts market is deeper. Today's bar may still be incomplete. The 171.02 low has held twice, and a bounce from the 168 to 171 zone is plausible. The reward-to-risk on the reassessment level isn't spectacular, with 194.48 about 12.7% above price and the rebuild zone at 152 to 158 about 8 to 12% below. That is why this is a trim and not a short. I'm also not leaning on insider selling, since it looks plan-based and is a weak signal.

For anyone applying this: if you're flat, stay flat and rest bids in the 152 to 158 area. If you hold a full position, sell down toward half, with the first half of the trim near 172 to 173 and the rest on limits into 176 to 181, finished a session before the print. Treat a daily close above 194.48 as the signal to reassess. The 167 to 168 area is within one ATR of price, so it's noise and not a stop.

The cautious-sounding choice of holding everything and hoping the print fixes it is actually the more exposed one. I'm for selling.

FINAL TRANSACTION PROPOSAL: SELL Aggressive Analyst: We've converged on most of the plan. All three of us trim to about half, nobody holds full size into the print, and nobody is shorting. Neutral is right that "hold everything" was a straw man, so I'll drop it. What's left is execution and how much of the bear case is proven, so I'll concede where you've earned it and hold where you haven't.

Conservative, you're right that "start now because the date is uncertain" and "sell the second half into a rally" pull against each other. The fix is a first tranche now, limits for the rest, and a hard deadline of October 28 or two sessions before a confirmed date, then market. Neutral's 175 to 178 range is also better than my 176 to 181, since the last bounce died at 180.78 and the 10-EMA is 177.99. I'll take it. 194.48 is a reassessment level, not a stop, and nobody should put a buy-stop there against a half position.

I'll also retire two of my own points. The 23x annualizes the weakest quarter in the dataset, so it's a stress case, not a base case. And "distribution" overreached, because 11 to 12 million shares isn't heavy supply. The defensible claim is that nobody is paying up for the win. The one bullish tape item in the sentiment report, the $182.50 calls, expires Friday and is now about 5.7% out of the money.

Now where I hold. You both say the FCF collapse could be working capital, so look at which way the evidence points. Current liabilities rose $1.6B in Q3. A rise in payables, accruals or deferred revenue is a source of operating cash, so it would have flattered the $991M, not depressed it. The one kind of jump that wouldn't touch operating cash flow is debt moving into the current bucket, and that's a refinancing question, not a timing excuse. Non-cash current assets rose only about $0.8B, so I don't see a working-capital drain big enough to explain this. I'll grant the statements don't reconcile, so I can't prove it. Even if you write off Q3 cash flow as timing, operating income is down 23% over nine months, capex is up 101%, and Q2 FCF was already down 18% before Q3 hit.

Neutral, on the TTM point, nine months of financing outflow is $10.05B on its own. Setting that against a full year of FCF at $10.24B mixes periods. Add a fourth quarter of outflow and you're above FCF unless Q4 was unusually light. Cash is also down from $7.2B in December to $4.5B. I agree we can't say whether buybacks, debt or cash is absorbing the gap. But "we don't know what's giving" argues for less size, not for full size.

You also said the stock has round-tripped to its 9/8 level, so it isn't priced for euphoria. I agree, but compare it with where the stock traded on the same fundamentals. The quarter ended June 28 was public by the late-July gap that looks like the print. The stock then closed at 146.81 and based between roughly 157 and 170 through August. At 172.62 it's about 18% above that post-print low and slightly above the top of the base. I can't say what drove September, but the filed numbers haven't improved since August. The market is already assuming opex turns, and that has to reverse a line growing +12%, +16% and +22%. Your point that a 4 to 7% edge is modest is fair. That's why this is a trim and not a conviction call.

Conservative, Neutral is right on the quarter rule. Going from half to a quarter buys about three points of standard-position protection, costs the participation we kept the half for, and triggers 3.3% below price on a stock with a 4% ATR. That's a sell-the-low rule. If 166.9 breaks, finish any unsold trim and stop there.

Neutral's catch on the post-print rule is also good. Q3's own numbers would trigger the deepest cut. I'd read it as: more of the same isn't a reason to add back, and it isn't a reason to dump into the gap either. The pre-print trim exists so we don't have to sell the gap. After the print I'd key on the FY27 opex guide and on where the stock holds, and use bounces to trim further.

The rebuild bids are where I'll fight you hardest, Conservative. We're not trimming to avoid the event. We're trimming because the price is above our estimate of value, and the event only makes the position size matter. A fill at 152 to 158 is 8 to 12% lower, below the trader's own $160 to 165 central value, near the August lows and around 2x ATR. If macro drags it there, some print risk is already priced and you're buying under value. I'll meet you on size and timing, though. Three-quarters of standard is too much to leave resting. Ladder it at roughly 10% near 157 to 158 and 10% near 153 to 155, cap the add at about 20% of standard, and cancel both on the same deadline as the sell-by date. That's a bit bigger than Neutral's starter, with the same discipline.

In practice, express everything as a share of standard allocation, since we don't know anyone's holdings. If you're full, sell about half the trim now near 172 to 173, work the rest on limits to 178, and market out whatever is left by October 28 or two sessions before a confirmed date. A close below 166.9 accelerates the unfinished trim but doesn't push below half. Reassess on a close above 194.48. If you're flat, stay flat, with small laddered bids that get canceled before the print. The cost of being wrong is that we keep half and can rebuy. The cost of waiting is taking a 10% gap at full size against fundamentals that haven't turned.

FINAL TRANSACTION PROPOSAL: SELL Aggressive Analyst: We're close enough now that I'll skip the victory lap and spend this on the few places where I think one of you is still off, and concede where you've earned it.

Neutral, you're right that current liabilities and non-cash current assets are blunt tools, so I'll stop arguing the working-capital bridge from the balance sheet. But look at what your point implies. The June quarter filing is already public, so the biggest unknowns can be checked today: whether Q3 operating cash was timing, what sits in that opex line, and what the $7.4B in Q2 was. I'd let that drive the plan. The first tranche at 172 to 173 goes now, because the trim stands on opex, gap risk and a modest valuation edge whatever the filing says. Then the filing sizes the second tranche. If the cash weakness looks like timing and the opex step-up is largely one-time, a third is plenty, which fits your embedded-gain point. If opex is run-rate spend and cash conversion is really weakening, go to the full half. For a taxable holder with a big gain, that's a tax constraint and not a change of view, and I'm fine with it.

On cash, I used the December number too, and Neutral is right that September 2025 is the cleaner base. From there cash is down about $1.0B, while the flows imply about $3.3B, so the truth sits somewhere in the $2.3B reconciliation gap. I'll call it a monitoring item. On the FCF range, you two have both made fair points, but look at what the top end needs. Getting to roughly $10B for the year means Q4 FCF around $3.2B, within about 7% of last year's $3.4B. That comes right after a quarter down 81%, with capex running at about double last year's pace. It requires Q3 to have been entirely timing and to reverse completely in one quarter. That's possible, and I wouldn't underwrite it. So the yield is somewhere between 4% and 5.4%, and a range that wide is itself a reason to run half size.

Conservative, you've talked me down on the rebuy ladder. A single order of about 10% of standard, canceled at the deadline and on a close below 166.9, is fine. I'll point out one thing, though. The bid sits around 157 to 158 and the cancel trigger is 166.9, so to fill, the stock has to fall from above 166.9 to the bid inside one session, with no daily close in between. In practice that's a flush-day order. I'd rather own a flush than not, but I won't pretend it's central, and at 10% it's worth about a point of standard allocation either way. The principle I'll defend is that dry powder exists to be used. If you trim above your value estimate and never intend to redeploy below it, you haven't made a plan, you've made an exit.

Where I'd stay more aggressive than both of you is after the print. Neutral wants 75% after the first full session and the last 25% only on a second confirmation, like cash flow normalizing in the filings. Conservative wants 75% and then a pause. The trader wrote down thresholds for a reason: opex at or below about $3.4B and revenue at -2% or better. If those are met and the guide supports them, waiting for a filing-based second confirmation means paying up after the re-rating for information the P&L already gave. I'd go to 75% after the first settled session, and to full size once the stock holds the post-print level for a few sessions or the cash flow statement lands, whichever comes first. A pre-registered condition beats a discretionary one that arrives late.

On the other cases, I agree with Neutral. Don't sell the gap on a bad print. The whole point of trimming now is that we don't have to. If a good print sells off on heavy volume, I'd stay at half, and I wouldn't buy that dip either. That's the real version of the Arm-verdict message, where good news didn't lift the stock, and I'd trust it more than I trusted this week's 11 to 12 million share tape.

On the calendar, I'm happy with the close on Monday the 26th, or two sessions before a confirmed print. My recollection of the October FOMC is also the 27th and 28th, so a Monday finish avoids forced selling into the decision. Friday's monthly expiration, with those $182.5 calls expiring, means this week's tape is noisy either way. So don't hang the first tranche on a bounce. Work it over a session or two, because today's bar may not be final.

Here's what I'd say to anyone applying this. Think in shares of a standard allocation. If you're full, sell toward half, with a third as the floor if you have a large taxable gain or if the 10-Q shows the cash drop was mostly timing. Sell about half the trim near 172 to 173 over the next session or two. Work the rest on limits up to about 178, since the 175 to 178 area is where the 50-SMA and 10-EMA sit and the last bounce died at 180.78. Sell whatever remains at market by the close on the 26th. A close below 166.9 finishes any unfinished trim but doesn't push you below half. A close above 194.48 means reassess, not stop out. If you're flat, stay flat, with at most one small bid that comes off at the deadline.

None of this requires us to be right about the cash story, the macro read, or whether the next bounce reaches 178. It requires one thing: a 10 to 12% gap against a half position costs about 5 to 6% of standard, instead of 10 to 12% at full size, and you keep half the upside if the print is good. The cash from the trim is an option on the gap, because after the number, with the guide in hand, you can add on whichever side the market gets wrong. That is the aggressive part of this plan: we pay a small known cost to be positioned to act when the uncertainty resolves.

FINAL TRANSACTION PROPOSAL: SELL Aggressive Analyst: Neutral has the right idea: we've been giving one-point items the same attention as five-point ones. I'll go through what's left in order of importance.

Conservative, you're right about my "option on the gap" language, and I'll retract it. Selling half doesn't cost a small known amount. On a 10% gap up it costs about five points of a standard allocation, and on a 10% gap down it saves about five. The trim is symmetric around the event. What it buys is a modest edge, two to three and a half points if the $160 to $165 central value is roughly right, plus cash that lets us size after the number instead of before it. That's a positive-expectancy variance cut. I'd still push back on "we redeploy higher after a good print and into a worse guide after a bad one." Those don't cancel. The price we redeploy at depends on how the market reacts. A bad guide with the stock down 15% is a different purchase from a bad guide with the stock flat. A full-size holder has to sell to get that choice, and that is the gap-selling we all want to avoid.

On the 10-Q, I side with Neutral on the logic and Conservative on the default. The filing can't shrink the gap, and it can't tell us whether anything reverses in Q4. But the 4 to 7% edge does rest on opex persisting, and the filing is where one-time items would show up. So if it shows both cash timing and one-time items in opex, holding two-thirds instead of half is defensible on evidence, not just tax. If it shows one or neither, we stay at half. The filing moves us within that band and doesn't take us outside it.

On the volatility argument, I'm with Neutral. A 1.65 beta is already in the standard allocation, so the chart of +100%, -41%, +37% and -14% doesn't justify going lower. I'd also point out that the same chart is why I won't go below half. A stock that can double in two months is one where sitting at zero is also a bet. The incremental reasons for half are the price above value, the opex line still accelerating, and the history of 10% gaps. The two-events point is real, but it argues against adding before the Fed, and our plan already does that. The sells and the single bid all come off by the close on the 26th, before the 27th-28th meeting, which we should still verify.

Conservative's FCF scaling to roughly $9.3B and a 5% yield is a fair middle, and I'll take it. It's real support. But a 5% yield on a number that has fallen four quarters in a row is a cushion, not a floor.

On re-entry, I've lost some of this argument. Conservative is right that "the cash flow statement lands" is a vacuous trigger, because the release normally carries it the same evening. Neutral is right that $3.4B opex is a 7% sequential drop and a full give-back of the Q3 step-up, so the trader's threshold is a "clearly good" screen, not a pass-fail test. Opex is also derived by subtraction. I'll accept Neutral's rule: 75% after the first settled session on a good print, and full size when management gives a specific opex number or direction, the stock holds the post-print level, and the 10-K doesn't contradict the release. I'd add one thing so the filing doesn't become an excuse to wait indefinitely. If it lands and is clean, we go to full size the next session. The cost of waiting is a week or two of drift, so we're arguing about a small amount either way. Check the filing date along with the earnings date.

On the bad-print rule, Neutral and Conservative have converged on cutting toward a quarter within three to five sessions if the guide shows opex still rising, and I accept the structure. I'd change one thing: don't touch the stock on gap day. That session has the widest spreads, the most algorithmic flow and the most overshoot. Start on day two, finish by day five, and cut only if the guide is bad and the stock hasn't already repriced. If it holds on a bad guide, the market is telling us it's priced, and we stay at half. This keeps the promise the pre-print trim makes, which is that we never have to sell the gap itself.

The bid is settled at about 10% of standard, off at the deadline, and not worth more argument. A 166.9 close finishes any unsold trim and cancels it, though as Conservative noted, the cancel can't protect us in the flush scenario that fills it.

The bold part of this plan isn't the selling. It's being at half going into a binary event, with no dependence on a bounce or a macro call, and then acting quickly in either direction once the guide is out. Full size into this print would be passive. It would mean taking a 10% gap against fundamentals that haven't turned, on a stock that hasn't priced much of that risk.

For anyone applying this, think in shares of a standard allocation. If you're full, sell toward half. Sell the first piece near 172 to 173 over the next session or two, since today's bar may not be final and Friday's expiration makes the tape noisy. Work the rest on limits up to about 178. Sell whatever is left at market by the close on Monday the 26th, or two sessions before a confirmed earnings date if that's earlier. A close below 166.9 finishes the unfinished trim and cancels any bid, but doesn't push you below half. A close above 194.48 means reassess, not stop out. Hold two-thirds instead of half only for a documented tax reason or if the 10-Q shows both cash timing and one-time opex. Use at most one bid of about 10%. If you're flat, stay flat.

FINAL TRANSACTION PROPOSAL: SELL Aggressive Analyst: We're now arguing over one or two points of standard allocation, so I'll concede what I owe and spend the rest on the two places where a rule could misfire.

Conservative is right that I said FCF fell four quarters in a row, and the data doesn't show that. It's up 2.5% year over year in Q1, then down 18%, then down 81%. Two declines, accelerating, is the claim to make. I also retract "the stock hasn't priced much of this risk." I agreed the edge is only 4 to 7%, and a stock down 14.5% in 14 sessions has priced some of it. Some is priced and some isn't, which is what half a position expresses. I don't need the stronger claim, because the trim stands on three things the cash story doesn't touch. Implied opex is growing +12%, +16%, +22% against revenue of -3.5% and -4.0%. Operating income is down 41%. And the stock sits at the top of its August base with a history of 10% gaps on prints.

Neutral's repair of the pre-written test is right. The $160 to $165 central value is the persistence case, and a bad guide should be worth less. So here's my number, which is my judgment and not a tool output. A bad guide gets about 20x the $7.50 GAAP run-rate, roughly $150. The rule: if the guide shows opex still rising and the stock is still above $150 after the first full session, cut toward a quarter on days two through five, and sell whatever is unfilled at market on day five. If it has already gone below $150, hold at half. Write the number down before the print. It means a 12% gap to about $152 still triggers the cut, which is intended, because that stock hasn't repriced to the bad case.

On the re-entry gates, Neutral is right that stacking them turns the last quarter into a cap. One more point against them. As I recall, QCOM guides the next quarter and not the year, so we get one quarter of forward evidence and shouldn't ask more of it than that. I'll take Neutral's fallback. Back out the implied operating margin from the revenue and EPS guide, using the reconciliation in the release, and ask whether it clears the 16% area. My rule is 75% after the first settled session, and full size when the implied margin is rising and the stock has held its post-print level for three sessions. The 10-K can veto but can't gate, with a time box. I also suspect QCOM files the 10-K within days of the release, not weeks, though that's memory. Check last year's filing dates on EDGAR, because if I'm right the Conservative-versus-Aggressive disagreement over waiting for it disappears. Either way we're arguing about roughly a point of drift.

On half versus two-thirds, I accept Neutral's concrete test. Named one-time items must explain most of the roughly $260M step from Q2 to Q3 opex, and nameable, reversible items must explain the $991M of operating cash flow. Conservative's point also stands. Even if the filing explains all of Q3's step-up, opex is still about 16% above a year ago, which is why the ceiling is two-thirds. The 10-Q is public and takes about twenty minutes, so read it before placing the first order. Decide the target once, then don't revisit it. The wash-sale point is fair too. Pick lots deliberately and ask a tax person, but it doesn't change the target.

On the bid, Neutral's refinement, that it's live only after the trim is done, makes it nearly moot. If the trim finishes at the deadline, the bid is live for zero sessions. I'll keep it as an option and not a plan.

The other analysts have framed the aggressive position as leaning on a cash bear case we can't prove. It doesn't. I'd sell half with the cash story fully unresolved, because the case is opex, a modest valuation edge and gap size. What makes this aggressive is that we act before the catalyst instead of reacting to it. Every post-print move is written in advance, and we get back to size quickly if the guide earns it. Holding full size and hoping the print fixes a line growing 22% a year is the passive choice. Stacking so many confirmations that we're still at 75% three weeks after a good print is passive too, just slower.

The plan, in shares of a standard allocation. If you're full, read the 10-Q first. Then sell the first piece near 172 to 173 over Thursday and Friday, knowing Friday's monthly expiration will make the tape noisy. Work the rest on limits up to about 178. Sell whatever is left at market by the close Monday the 26th, or two sessions before a confirmed earnings date if that's earlier. A daily close below 166.9 finishes any unsold trim and cancels any bid, but doesn't push you below half. A close above 194.48 means reassess, not stop out. If you're flat, stay flat.

After the print, a good number with the stock holding means 75% after the first full session, then full size on the margin test and three sessions of holding. A good print that sells off, or a bad print that holds, means stay at half and don't chase. On a bad guide, don't touch gap day, and apply the $150 test on days two through five.

FINAL TRANSACTION PROPOSAL: SELL

Conservative Analyst

Conservative Analyst: I agree with the aggressive analyst on direction, and that shapes where I push back. Cutting to about half a standard allocation ahead of a binary print is right for anyone who cares about protecting capital. But this is variance reduction, not aggression. The plan as written also leans on predictions that a cautious plan shouldn't depend on.

The first is the bounce. The aggressive analyst says to start now because the earnings date is unverified and could come sooner than early November. Then the plan sells the second half on limits at 176 to 181, which only fills if the stock rallies. Those two ideas conflict. If the date is uncertain enough that you can't wait, you can't also count on a rally to get you out. The last bounce topped at 180.78 and failed, and the 50-SMA, the 10-EMA and the recent closes near 181 all sit overhead. Those limits may never trade, and you'd reach the print holding more than half. I'd set a hard deadline, such as the end of October or the confirmed earnings date if that's earlier, and sell anything unfilled at market. At this point certainty is worth more than price improvement.

The second is the "stop" at 194.48. That's the daily SuperTrend flip, 12.7% above the price, and it protects nothing on the half you keep. It's a reassessment level and should be called one. The level that matters for the remainder is 166.9 to 168, where the lower Bollinger band, the 200-day and the double low at 171.02 cluster. The trader calls it noise because it's within one ATR. That's fair for an intraday stop, but not for a daily close, since it's the one place on this chart where several independent measures agree. Below it the next reference is the 155 to 160 area, another 8 to 10% down. I'd want a rule that a daily close below about 166.9 takes the remainder to a quarter of standard before the print, because after a gap you don't choose your price.

Third, the pre-print rebuild bids at 152 to 158, up to 75% of standard. This is the part I like least. A resting bid is an automatic purchase. If hot inflation or a chip selloff drives the stock there before earnings, it fills, and you've added back into the event you trimmed to avoid. Dry powder should stay dry until the number is out.

On the evidence, I think the aggressive case overreaches in places. The 23x comes from annualizing the June quarter, the weakest operating quarter in the dataset, so I wouldn't lean on it any more than on a 16.9x built on an EPS basis nobody can identify. Valuation sits in a murky middle and settles nothing. The 81% FCF drop is real, but the fundamentals report says it can't tell working-capital timing from something structural. Current liabilities jumped $1.6B in that same quarter, and the cash flow statements miss reconciling by about $2.3B, so the $3.2B of returns over FCF is approximate. On the "distribution tell," the last two sessions traded 11 to 12 million shares, against 54 million on 9/18. That's a tape under mild pressure, not heavy supply. The stock was already down 7% on 9/28 before the verdict, with hot CPI and a memory-chip selloff in the background. We can't separate who is selling from a rates and semiconductor tape. The better argument is that we can't verify the inputs before the print, and unverifiable inputs are a reason to be smaller, without needing the bear case proven.

The aggressive analyst also missed a risk. About $10B of returns against $6.8B of FCF means something has to give. The roughly $3.8B dividend is the safest piece, so the buyback is the likelier cut, and it's what has been shrinking the share count 2 to 4% a year. If it slows, the EPS path gets harder. The Ambarella headline is unconfirmed and I wouldn't trade on it, but an acquisition would use cash while cash is falling.

On the neutral side, I expect an argument to hold full size and let the print decide. That isn't the low-risk choice. The balance sheet being sound is about solvency, and solvency isn't the risk here. Price is. A year of dividends is about $3.60 a share, roughly half of one average day's range. The monthly uptrend and the position above the 200-day feel like cushions, but the monthly SuperTrend stop is 48% below price and offers no practical protection. This name has gapped about 10% on prints several times this year, with a 1.65 beta, a hawkish rate backdrop and oil near $103. If the opex trend continues and the print disappoints, a full position takes that gap at full size. If it's good, we give up some upside and can add back after the numbers.

So I'm with the reduction, tightened in four ways. First, finish the trim on a calendar, not on a rally. Second, close below roughly 166.9 cuts the remainder to a quarter. Third, no rebuilding before the print. Fourth, relabel 194.48 as a reassessment trigger. Since we don't know the actual holdings, express all of this as a share of standard allocation and size the residual so a 10 to 12% gap against it is survivable. Conservative Analyst: Before I push back, credit where it's due. We've all moved toward the same plan: trim to about half of a standard allocation, no full-size hold into the print, no short, and 194.48 as a reassessment level and not a stop. Aggressive dropped the 23x and the distribution claim, and Neutral dropped the hold-everything framing. The fight is now over execution, so that's where I'll focus.

First, two concessions. Aggressive is right about the working-capital argument, and I shouldn't have let it stand as a possible comfort. Current liabilities rose about $1.6B in the quarter, while non-cash current assets rose only about $0.8B and cash fell. If that liability jump is operating, it should have flattered the $991M of operating cash flow, which makes the number worse. If it's debt moving into the current bucket, that's a refinancing question. Neither reading calms me down. Neutral is also right that I leaned on a buyback cut and the Ambarella headline. Those were inferences, and I'll drop them. The observable fact is enough: cash has fallen from $7.2B to $4.5B since December, and that is what has been giving.

Neutral, I'll also push back on the TTM point, because it runs the wrong way. Setting nine months of outflow against twelve months of FCF understates the gap, as Aggressive said. There's a second problem. The $10.24B TTM FCF includes a Q4 FY25 of roughly $3.4B by the report's own derivation, and that quarter drops out of the window at this print. Nine-month FY26 FCF is $6.83B. If Q4 FY26 looks like Q3 or Q2, FY26 FCF lands around $7.3B to $8.7B. That takes the 5.6% FCF yield to roughly 4% to 4.7%, and the dividend goes from about 37% of FCF to something like 44% to 52%. It's still covered, but the headline valuation support we're all citing is stale before the print arrives. That is a reason to be smaller, not a reason to hold.

On the 166.9 rule, you've convinced me. A one-ATR day reaches it, and a single close there is weak information. Cutting the remainder to a quarter on that trigger is selling the low. I'll withdraw it. I'd keep a smaller version: a close below 166.9 cancels any resting buy orders. If the cluster of the 200-day, the lower band and the double low breaks, the last thing we want is a standing order to buy into it.

That brings me to the rebuy ladder, where I'm holding my ground. Aggressive says a fill at 152 to 158 is below our value estimate, so we'd be buying under value. But the central value is $160 to $165, so a fill at 155 is a 3% to 6% edge. Neutral called a 4% to 7% edge modest on the sell side, and it's equally modest on the buy side, against a 10% two-sided gap. There's also adverse selection. A resting bid fills in the states of the world where something went wrong: a hawkish Fed surprise with the October meeting live, a semiconductor rout at 1.65 beta, or QCOM-specific news. In each case the bid fills just as the picture gets worse, and a gap through 155 on the print puts you under the July post-print close of 146.81. We also said the cost of being wrong is that we can rebuy. That applies here too. Buying after the number costs a few points of price for a lot less variance. My preference is no pre-print bids. If the group wants one, make it a single order of about 10% of standard, active only once the trim is complete, canceled on the deadline, and canceled early on a close below 166.9. I won't sign off on 20%.

On the calendar, there are two practical points. First, stop guessing at the earnings date. QCOM publishes it on the investor relations site, so confirm it today. Second, if I have the calendar right, the October FOMC decision is on the 28th. I'm working from memory because the world report only says late October, so verify it. If so, a forced market sale on October 28 lands on a likely rate decision, with the market pricing another hike at 86%. I'd move the hard deadline to the close of Monday the 26th, or two sessions before a confirmed print, whichever is earlier. Also, Friday is the monthly options expiration, and the last one produced a 54-million-share day that reversed the next session, so I wouldn't read much into this week's tape either way.

Finally, the limit ladder is worth very little. Aggressive's 176-181 versus Neutral's 175-178 is a 2% to 3% price difference on a quarter of a standard position, which is under one percent of a standard allocation. The gap on the residual is 5% to 6% of standard. Don't spend more attention on fill price than on the deadline.

For after the print, I agree with Neutral that the guide and the reaction should drive the decision, not the quarter alone. I'd add that one good print isn't a reason to go from 50% to 100%. Step to about 75% after the first full session has settled and the guide and balance sheet have been read, since the Q4 cash and debt figures will arrive with the P&L.

In practice: if you hold a full position, sell about half the trim now, work the rest on limits up to 178, and finish by the close on the 26th or two sessions before a confirmed print. Size the residual so that a 10% to 12% gap against it is a loss you agreed to in advance. Stops don't protect against gaps, but sizing does. If you're flat, stay flat.

FINAL TRANSACTION PROPOSAL: SELL Conservative Analyst: We're down to details, so I'll stick to where the plan still carries more risk than the evidence supports, and give back a couple of points I owe.

Neutral is right about the cash base. Measuring from December picks the seasonal peak, and Aggressive has agreed. From September 2025, cash is down about a billion. The liquidity line I'd watch instead is current liabilities, measured from that same September base: $9.1B to $11.4B, up about a quarter, with the current ratio falling from 2.82 to 2.02. I'm calling that a monitoring item, not a thesis driver.

Neutral is also right on my FCF range, because I anchored on the two weakest quarters. If I scale Q4 by last year's pattern, where Q4 was about 37% of the first nine months, I get a Q4 near $2.5B and a year near $9.3B. That is roughly a 5% yield with the dividend near 40% of FCF. It's crude, but it's a better middle than either end. So the valuation support is real and a bit below the 5.6% headline. It's one more input with a wide band, which is why we're at half.

Aggressive, I'll start with the "option on the gap" language, because it's doing too much work. The trim isn't an option. If the print is good and the stock gaps up 10%, the half we sold costs about five points of a standard allocation. If it's bad and gaps down 10%, we save about five. That's symmetric, so the cost isn't small or known. What we're buying is lower variance plus a modest edge, since the trader's $160 to 165 central value is only 4 to 7% below price. That's a good enough reason to trim. But the proceeds are not ammunition. After a good print you redeploy higher, and after a bad print you redeploy into a worse guide. We all agree to redeploy after the number, so I don't accept that the alternative is an exit. The dispute is about timing, not about whether.

On the bid, I'll take 10% as agreed. Your own observation shows the 166.9 cancel rule can't protect us in the scenario that fills it. The order only fills on a flush of roughly 5 to 8% inside a session, with no close in between to trigger the cancel. The only protection is the size, so keep it at 10% and leave it.

On sizing the second tranche off the 10-Q, I like reading the filing, and the first tranche shouldn't wait for it. But the 10-Q describes last quarter. The trim is driven by the gap distribution and the FY27 opex guide, and a June filing speaks to neither. Even if Q3 cash was pure timing, a 10% gap on a 1.65 beta stock doesn't shrink. So the default stays at half. A third should be a tax decision someone has written down, and they should know they're carrying about 7 to 8 points of standard through a 10 to 12% gap, not 5 to 6.

The "whichever comes first" trigger to get from 75% to full size is where I push back hardest. As I understand it, the earnings release normally carries operating cash flow and capex, so the cash flow statement may land the same evening as the P&L. If so, that condition is already met. The rule then becomes: good print, stock holds a few sessions, full size. Opex is derived by subtraction here, and it's the same line we said we can't decompose, now serving as the trigger for 100%. Use the arithmetic I used on the limit ladder. If we wait for the 10-K, which I recall arrives a couple of weeks later, and pay another 3 to 4% on the last quarter of a position, that's about a point of standard. If the quarter was flattered by something one-time and we're full size going into the next leg, that costs more. Neutral's 50-SMA alternative is also the weaker leg, since a gap up satisfies it on day one. I'd hold at 75% until the filing shows what's in opex and cash flow.

Neutral, I agree with most of your table, and I accept that a 166.9 cut was selling the low. One issue is the bad-print case where we "cut toward a quarter on a bounce if 155 to 160 fails." That's the same bounce-dependence we spent three rounds removing before the print. Below 155 the next references in our own data are the 146.81 post-print close and the 142 intraday low, so there's little to bounce from. If the guide shows opex still rising, put a time limit on it, say three to five sessions, and sell what's unfilled at market.

One thing neither of you has priced: the half we keep faces two events, not one. I recall the FOMC decision being on the 28th, but verify that. Finishing on the 26th avoids forced selling into it, but the residual then rides through the Fed with a hike back on the table. Our 5 to 6% gap sizing was built around earnings. That's another reason not to go above half except for taxes.

I agree with Neutral's list of 123, 249, 147, 202, 173. A stock that has moved plus 100%, minus 41%, plus 37% and minus 14% in six months is a poor candidate for conviction at any anchor, and that's the best argument for the size we've settled on.

In plain terms, if you're full, sell toward half, with a third only for a documented tax reason. Sell the first piece over the next session or two near 172 to 173 and work the rest on limits up to about 178. Sell whatever remains at market by the close on Monday the 26th, or two sessions before a confirmed print if that's earlier. A close below 166.9 finishes any unfinished trim and cancels any resting bid, but doesn't push you below half. Treat 194.48 as a reassessment level, not a stop. Use at most one bid of about 10%, off at the deadline. After the print, step to 75% on a good number once the first session has settled, and take the last quarter only once the filing shows what's in opex and cash flow. On a bad print, don't sell the gap, but put a time limit on any further cut. If you're flat, stay flat.

FINAL TRANSACTION PROPOSAL: SELL Conservative Analyst: I've given up most of my ground, so here is what's left. I'm not asking for anything below half. I dropped the 166.9 cut to a quarter, the rebuild is down to one 10% order, and I now agree the 10-Q matters. Neutral's charge that the conservative version keeps shrinking a position the evidence doesn't ask us to shrink was fair three rounds ago, but it isn't now. What remains is how fast we get back to full size, plus a few claims that are looser than they sound.

First, a correction to something Aggressive said, even though it cuts against my side. You said FCF has fallen four quarters in a row, and the report doesn't show that. Year over year, FCF was up 2.5% in Q1 FY26, then down 18%, then down 81%. That's two straight declines, accelerating. Q1 is also seasonally the strongest quarter, so the sequential slide isn't a clean read. The acceleration is the real concern, and we should cite that.

Neutral, you're right that I double counted volatility. Realized swings are already in the standard allocation. The incremental reasons for half are price above value, the opex trend, and the gap history. I'll drop the chart as an argument. The two-events point isn't a reason to go lower either, only a reason not to add before the 28th, which we all accept.

On two-thirds versus half, I was wrong to call it purely a tax decision. The 10-Q is the one place where the premise of the edge can be checked. But the best case it can deliver is limited. Year-ago implied opex was about $2.95 to $3.0B a quarter. Q1 and Q2 FY26 were already $3.3B and $3.4B, up 12% and 16%, before Q3 stepped up another $260M to $3.65B. Even if the filing shows a one-time charge that explains that entire jump, opex falls back to about the Q2 level, which is still 16% above a year ago against falling revenue. The filing can remove the Q3 spike, but it can't remove the climb before it. So I'd use the two-thirds end only if the filing quantifies both the cash timing and the one-time opex items, not if it merely allows for them. Decide that before you place the first tranche, then stick with it.

On re-entry, I can live with Neutral's structure, with two edits. First, "a specific opex number or direction" is too easy. Management always says something about discipline. I'd require a number or a range that implies opex below the Q3 level, because slower growth is still growth. Second, there's a basis problem. As I recall, QCOM guides on a non-GAAP basis, while our $3.65B is a GAAP figure derived by subtraction. The release carries a reconciliation, but until someone reads it the guide and our number aren't comparable. That is the same unknown as the forward EPS basis, and I'd want it resolved before the last quarter of the position goes back on. I recalled the 10-K coming a couple of weeks after earnings and Neutral said a week or two. If it lands close to the print, this disagreement disappears, so check the date.

On the bad-print rule, I accept no selling on gap day, starting on day two and finishing by day five. The phrase "if the stock hasn't already repriced" worries me, because it's a judgment call made in the worst conditions. Write the test down beforehand. If the guide shows opex still rising, what is your central value? If the stock is still above that after day one, the cut goes ahead. If it's below, you hold at half. That keeps the rule from becoming whatever feels right after a 12% gap.

Aggressive, you also close by saying the stock hasn't priced much of this risk. But you agreed the edge is only 4 to 7%, and the stock is down 14.5% in 14 sessions and back at its 9/8 level. A modest edge means a fair amount is already priced. The case for half is variance reduction plus a modest edge, and I'd keep selling it that way.

One practical item nobody has raised. If you're a US taxable holder, some lots are probably underwater, given the run from 250 to 147 and back up. Selling those lots and buying back within 30 days, including the 10% bid and a post-print step back to 75%, can trigger the wash-sale rule and defer the loss. That doesn't change the plan, but it's a reason to choose lots deliberately. I don't know the caller's jurisdiction, so check it.

In practice, think in shares of a standard allocation. If you're full, sell toward half, with the first piece near 172 to 173 over the next session or two. Work the rest on limits up to about 178, and sell whatever is left at market by the close on Monday the 26th, or two sessions before a confirmed print if that's earlier. A close below 166.9 finishes any unsold trim and cancels the bid, but doesn't push you below half. A close above 194.48 means reassess, not stop out. Use at most one bid of about 10%, off at the deadline. Hold two-thirds only for a documented tax reason or if the filing quantifies both cash timing and one-time opex. After a good print, step to 75% once the first session settles. Take the last quarter only on a quantified opex guide below the Q3 level, reconciled to our basis, with the 10-K not contradicting it. On a bad guide, don't touch the gap, and use your pre-written value test on days two through five. If you're flat, stay flat.

FINAL TRANSACTION PROPOSAL: SELL Conservative Analyst: We're now holding nearly the same position, so here is where I stand: half of standard, not lower, and nothing resting that could add into the event. What's left is how we behave after the number. One of the rules we've written has a real flaw, and a few smaller things need adjusting.

The flaw is the margin test. Neutral offered a fallback of backing the implied operating margin out of the revenue and EPS guide and asking whether it's rising from the 16% area, and Aggressive accepted it. As I recall, QCOM guides the next quarter, which here is the December quarter, the seasonally strongest one. Last year's December quarter did $12.25B of revenue at a 27.5% margin. The June quarter did $9.95B at 16.3%. Take a simple case: December revenue 4% below last year, gross margin unchanged at 53.1%, and opex stuck at Q3's $3.65B. That works out to about a 22% margin. The test would say "margin recovering" when nobody has cut a dollar.

The growth-rate version has the same problem. Last year's December-quarter opex was $3.32B, so flat opex at $3.65B shows up as plus 10% year over year, down from plus 22%, again with no cost progress. The calendar and the base year flatter both tests. The test has to be in dollars, with implied opex measured against Q3's $3.65B and Q2's $3.39B. I'd call it a pass at roughly $3.5B or lower, which gives back about half of the Q3 step-up. It's a direction check, not a precise gate. A ten-cent range in the EPS guide is worth about $120M pretax, roughly half the step we're trying to detect. Compare it against the same-basis year-ago figure the release prints next to it.

Neutral, you're right that stacked gates turn the last quarter into a cap, so I'll give ground on timing. I said the 10-K comes a couple of weeks after the print, you said a week or two, and Aggressive suspects days. None of us can check, so look at last year's filing date on EDGAR. If it lands the same week, the argument disappears. If it hasn't landed ten sessions after the print, decide on the release and the call. The filing can veto but it shouldn't gate.

Aggressive, I like writing the $150 down, but look at what it does. It sits 13% below the price, so even a 12% gap still says cut. In practice the rule is "cut toward a quarter on days two to five unless the stock has already fallen more than 13%." That's a sell-after-the-gap rule. I'm fine with that, because the pre-print trim is what carries the protection, and the post-print cut is a second step. We should just describe it honestly.

There's also a check on the gap size we've all been planning around. In the tool output I can measure two of the earnings-looking dates. February opened 10.7% below the prior close, and July opened about 5.9% below. April I can't measure from what's printed. So 10 to 12% is the high end of what we can see, which is fine for a loss agreed in advance. But once the date is confirmed, use the options-implied move instead of three data points. The half-size conclusion doesn't depend on it, because the opex trend and the edge carry it.

On the bid, Neutral's refinement makes it nearly moot, so I'd take it out of the written plan so nobody leaves it resting by accident. I'll also leave the "passive versus aggressive" labels alone. Acting before the catalyst and sizing for the gap are the same order.

If you hold a full position, read the 10-Q first and decide once between half and two-thirds. Go to two-thirds only if named one-time items explain most of the roughly $260M opex step and nameable, reversible items explain the $991M of operating cash flow. Sell the first piece Thursday and Friday without waiting for a bounce. Work the rest on limits up to about 178, and sell anything left at market by Monday the 26th, or two sessions before a confirmed print, whichever is earlier. A close below 166.9 finishes the trim but doesn't take you below target. A close above 194.48 means reassess.

After a good print with the stock holding, go to 75% once the first session settles. Take the last quarter when implied opex is about $3.5B or lower, or at ten sessions, whichever comes first. After a bad guide, do nothing on gap day. Cut toward a quarter on days two to five unless the stock is already below your written number, and sell anything unfilled on day five. If you're flat, stay flat.

FINAL TRANSACTION PROPOSAL: SELL

Neutral Analyst

Neutral Analyst: I agree with you both on direction, which is why I want to press on how each of you gets there. I think the trim is right, but both versions have a hole.

Aggressive first. The income statement does lean your way: operating margin fell from 30.5% to 16.3%, and opex growth is accelerating into falling revenue. But much of the bear case rests on things we can't verify. Opex is derived by subtraction, and nothing says whether restructuring is in it. The FCF collapse may be partly working capital, since current liabilities jumped $1.6B in the same quarter. The cash flow statements also miss reconciling by about $2.3B, and financing outflows include any debt paydown, which isn't itemized. Your $3.2B shortfall could be a lot smaller, and on a TTM basis FCF of $10.2B roughly matches what's going out. Falling cash is a flag to check, not a verdict.

Your distribution tell is the weakest piece. The stock rose on 10/13, from 174.43 to 176.86. Today's 2.4% drop came with a memory-chip selloff and hot CPI in the background. Retail summaries say damages were $2, so the win may simply be smaller than the headline. That isn't evidence of informed sellers. The weekly SuperTrend stop sits at 223, above even the September high of 202, which suggests it has pointed down through the whole September rally. It describes the regime since the May peak and says little about this week. And at 172.62 the stock is back where it traded on 9/8, at 174. The breakout has round-tripped, so this isn't a stock priced for euphoria.

The trader's own central value is $160-165, about 4 to 7% below price, against a roughly 10% gap either way. That is a modest edge. It argues for a measured trim, not conviction, and nobody here is proposing to hold everything, so that framing is a straw man.

Conservative, I like the calendar deadline, sizing for a 10 to 12% gap, and relabeling 194.48 as a reassessment level. Here is where I disagree.

First, the rule that a close below 166.9 cuts the remainder to a quarter. At half of standard, a 10 to 12% gap costs about 5 to 6% of a standard position. At a quarter it costs 2.5 to 3%. So the rule buys roughly three points of protection and gives up the participation you kept the half for. The trigger is also only 3.3% below price with a 4% ATR, so a normal bad day could hit it, probably right as RSI finally washes out. That is selling the low. If the cluster breaks, I'd have it accelerate any unfinished trim, not push below the target.

Second, you criticized the aggressive analyst for leaning on predictions, then leaned on a buyback cut and Ambarella cash use, which you said is unconfirmed. "Something has to give" is a fair risk flag, but with unitemized financing and a reconciliation gap, we don't know what is giving.

Third, no rebuild at all. I agree a 25%-of-standard add is too big to sit as a resting bid. But if macro drives the stock to 155-158 before earnings, that is about 10% lower, near the August base and the 2x ATR mark, and some of the print risk is already priced. A small starter of about 10% of standard, canceled a few sessions before the print, is defensible. Dry powder doesn't need to be absolute.

Both of you also accept the trader's post-print rules at face value, and they have a problem. The cut-to-25%-or-exit trigger is opex of $3.65B or more with revenue at -4% or worse. Q3 was $3.651B and -4.0%, so more of the same triggers the deepest cut. By the time we read the numbers the stock will have gapped, and selling after the gap is the mistake the conservative analyst warned about. The post-print decision should key on the guide and the price reaction, not on the quarter alone.

Here is the plan I'd run, in terms of standard allocation. Trim toward about half and stop there unless the print changes things. Sell about half the trim near 172-173, work the rest on limits into 175-178 where the 50-SMA and 10-EMA sit, and sell whatever is unfilled at market by about October 28, or two sessions before a confirmed earnings date if that's earlier. Treat 194.48 as a reassessment level. Don't add above the starter before the print. If you're flat, stay flat, with an optional small bid in the 155-158 area. After the print, size on guidance and reaction. Sentiment data is thin and noisy and shouldn't tip the decision either way.

FINAL TRANSACTION PROPOSAL: SELL Neutral Analyst: Aggressive and Conservative have now landed on nearly the same plan, so I'll spend my time on where each of you is still leaning harder than the evidence allows, and then say what I'd run.

Aggressive, take the working-capital argument first. Your direction is right: a payables or accrual jump should have helped operating cash flow, not hurt it. But the bridge you're using is current liabilities up $1.6B against non-cash current assets up $0.8B, and neither line is a clean operating number. Current liabilities can hold the current portion of debt or taxes payable, and non-cash current assets can hold securities that run through investing. A balance sheet also can't show cash tax timing at all, and that's a live candidate when the history includes a huge non-cash-looking item. You conceded you can't prove it, so I'd go one step further and say we shouldn't be arguing about it. The June quarter 10-Q is already public, and its cash flow notes and debt footnote answer this in twenty minutes. Anyone actually sizing this should read it before the print. If Q3 cash was timing, one leg of the bear case disappears, and the trim still stands on opex, valuation and gap risk, which is enough.

Your "18% above the post-print low" is also a chosen anchor. In six months QCOM has gone 123 to 249 to 147 to 202 to 173. Against the 157 to 170 August base it sits at the top, which supports a modest trim and not conviction. "The market is assuming opex turns" is an inference about a September rally you told us you can't explain. The Arm trial, sector flows or positioning could each have done it, and most of it has been given back.

On the 20% rebuy ladder, resting bids at 153 to 158 take a half position to about 70% of standard exactly when the stock is down 8 to 12% going into the print. The edge you'd be buying is 3 to 6% to a central value that rests on an opex assumption none of us can check. You called a 4 to 7% edge modest on the way down, and it's just as modest on the way up.

Conservative, you made Aggressive retire the 23x because it annualizes the weakest quarter. Then you gave us an FY26 FCF landing zone of $7.3B to $8.7B that assumes Q4 looks like Q3 or Q2, the two weakest cash quarters in the set. That's the same move. Q4 FY25 was about $3.4B, so if Q3 was timing and it reverses, FY26 lands closer to $10B and the yield barely changes. The honest range is $7.3B to roughly $10B. That width is a reason to be smaller, which we already are, but it doesn't make the valuation support stale.

The cash comparison has a similar problem. $7.2B to $4.5B measures from the seasonal peak, right after the strongest cash quarter. For nine months of flows, the right starting point is September 2025 at $5.5B, so cash is down about $1.0B. The cash flow statements imply a drop of about $3.3B, and that $2.3B difference is the reconciliation gap we keep mentioning. So "cash is what's been giving" is true, but the drop is smaller than the headline. $4.5B is the low in the dataset and worth watching, but it's a monitoring item and not a thesis driver.

On adverse selection, the resting sells are the mirror image of the resting bids. They only fill in bounces, which leaves you holding the unfilled piece in a down tape. That's why we want a deadline. The tape is also being pushed by CPI, chips and oil, which are macro forces, not company news. I'll still grant your principle that a bid shouldn't add event exposure. Both of you have effectively offered the same thing: about 10% of standard at most, canceled at the deadline and on a close below 166.9. A 10% starter is worth maybe a point of standard allocation either way, so let's stop fighting over it. The residual size at the print is what matters, and we all agree on it.

On the calendar, I also recall the October FOMC as the 27th and 28th, so I'd verify it, but finishing at the close on Monday the 26th works. QCOM has historically reported in the first week of November, so a confirmed date probably doesn't pull the deadline forward. Check the investor relations page anyway.

For after the print, I agree that the guide and the reaction should drive the decision, not the quarter alone. Here's how I'd handle the four cases. - Good print, stock up: step to about 75% once the first full session has settled, and take the last 25% only on a second confirmation, such as holding above the 50-SMA or cash flow normalizing in the filings. - Good print, stock sells off: stay at half and don't chase. - Bad print, stock gaps down: don't sell the gap. If the opex guide is still rising and the 155 to 160 zone fails, cut toward a quarter on a bounce. - Bad print, stock holds: that tells you it's priced, so stay at half and trim only if the guide is genuinely bad.

For anyone applying this, think in shares of a standard allocation, since we don't know holdings or tax basis. Trim toward half in tranches. Sell a first piece over the next session or two, since today's bar may be incomplete. Work the rest on limits up to about 178. Sell whatever is left at market by the close on the 26th, or two sessions before a confirmed earnings date if that's earlier. A close below 166.9 finishes any unfinished trim but doesn't push below half. Treat 194.48 as a reassessment level and not a stop. If the position carries a large embedded gain, lean toward trimming a third instead of a half, because the second half of the trim is the least valuable piece. If you're flat, stay flat, with at most a small starter bid that comes off at the deadline.

Half size cuts the cost of a 10 to 12% gap against you from 10 to 12% of standard to 5 to 6%. It keeps half the participation if the print is good, and it doesn't require proving the cash story or predicting a bounce. That's the balance I'd defend.

FINAL TRANSACTION PROPOSAL: SELL Neutral Analyst: We've converged enough that I'd rank what's left by how much it matters, because I think we're giving a one-point item the same attention as a five-point item. If the trader's $160-165 central value is right, the edge on the half we sell is 4 to 7 percent, or about two to three and a half points of a standard allocation. Protection against a 10 to 12 percent gap is about five or six points. The resting bid, the limit ladder, and the exact path from 75 to 100 percent are each about a point or less. What matters is the residual size, the deadline, and how we behave after the print, so I'll stay on those.

Aggressive, on the 10-Q: I raised it, so I'm glad you're using it, but be clear about what it can deliver. It can show what drove the $991M of operating cash flow, whether receivables, taxes or inventory, and whether the opex line carries restructuring. It can't tell you whether any of that reverses by the September quarter, and Q4 cash depends on that. So the filing should move you within a narrow band, a third to a half, and only when both things line up, timing in cash and one-time items in opex. One finding alone isn't enough. If the answer is murky, default to half.

Conservative, I disagree with your rule that a third is only a tax decision. You're right that the 10-Q says nothing about FY27 guidance. But the 4 to 7 percent edge rests on opex persisting, and the 10-Q is where one-time items would show up. That's the part of the edge we can check today. If a large share of the Q3 step-up is one-time and cash was timing, the edge has shrunk, and holding two-thirds is defensible on evidence, not only on tax.

I also think you're double counting volatility. You cite the move of +100%, -41%, +37%, -14% as the best argument for our size. But the standard allocation already assumes a 1.65-beta stock that swings like this. What's incremental is a price above our value estimate, an opex line still accelerating, and a print with a history of ten percent gaps. Those justify half, and the trailing chart doesn't add to them.

The same goes for the two-events point. The FOMC is real, and I recall it as the 27th-28th too, so finishing on the 26th is right. But a hawkish surprise moving a 1.65-beta stock a few percent is a different order from a ten percent earnings gap, and it hits a 50 percent residual and a 67 percent residual alike. It argues against adding before the 28th, which we already agreed on. It doesn't change the target.

On re-entry, you've both landed a hit on me. Conservative is right that the 50-SMA is a weak confirmation, because a gap up clears it on day one, and the cash flow statement probably arrives with the release. I'll drop both. But I think each of you misprices the delay. Aggressive, waiting for the 10-K costs a week or two, not a quarter, so the "paying up after the re-rating" cost is smaller than you suggest. Conservative, the 10-K adds less than you imply. It checks the release, and it won't create new information about the guide.

My rule would be 75 percent after the first full session on a good print. Full size comes when two things line up: management gave a specific FY27 opex number or direction on the call, and the 10-K doesn't contradict it. Price just has to hold the post-print level. That's pre-registered, as Aggressive wants, and it doesn't treat a filing as a formality, as Conservative wants.

One more caution on the trader's thresholds. Opex of $3.4B or less is a 7 percent sequential drop from $3.651B and roughly the Q2 level, so it asks us to give back nearly all of the Q3 step-up. A decent print with opex near $3.5B and a credible guide would miss it. That number is also derived by subtraction, which is the line we've said we can't decompose. I'd use the thresholds as a "clearly good" screen and let reported R&D and SG&A lines plus the guide drive the actual decision.

Conservative, I'll accept your time limit on the bad-print case. My "cut on a bounce" was the same bounce-dependence we spent three rounds removing, and below 155 there isn't much to bounce from. But I'd key it to the guide, not the price. If the guide shows opex still rising, cut toward a quarter within three to five sessions and sell what's unfilled at market. If the stock gaps down but the guide is fine, don't sell the gap. If it holds on a bad guide, the market is telling us it's priced, and we stay at half.

So this is the plan. If you're full, sell toward half in shares of standard allocation, with a third as the floor only if the filing shows timing and one-time items or you have a documented tax reason. Sell the first piece over the next session or two near 172-173. Work the rest on limits up to about 178. Sell whatever is left at market by the close on Monday the 26th, or two sessions before a confirmed print. A close below 166.9 finishes the unfinished trim and cancels any bid, but doesn't push you below half. Treat 194.48 as a reassessment level. Use at most one bid of about 10 percent, off at the deadline. If you're flat, stay flat. After the print, step to 75 percent on a good number and take the rest on the guide plus the filing. On a bad guide, cut within a few sessions and don't sell the gap itself.

The balance is that we keep half the upside, halve the damage from a gap, and make no bets on bounces, cash timing or macro. That's why I'd defend it over the aggressive version, which leans on an unproven cash story, and over the conservative version, which keeps shrinking a position the evidence doesn't ask us to shrink further.

FINAL TRANSACTION PROPOSAL: SELL Neutral Analyst: We've converged, so I'll skip the price tweaks and go after the places where a rule could misfire. Then I'll say what I'd run.

Aggressive, you close by saying the stock hasn't priced much of this risk. You also agreed the edge is only 4 to 7 percent, and those two claims don't sit together. The stock is down 14.5 percent in 14 sessions and back at its 9/8 level. It's also still about 18 percent above the post-July closing low and at the top of the August base. Some risk is priced and some isn't, which is what a half position expresses, so I'd drop the line instead of defending it. The FCF claim has the same problem. Conservative's correction holds. FCF was up 2.5 percent year over year in Q1, then down 18, then down 81. Sequentially it went from about $3.4B in Q4 FY25 up to $4.4B in Q1, so there is no four-quarter slide. The acceleration is the real signal and doesn't need embellishing. Your day-two rule is good, but "if the stock hasn't already repriced" is the discretionary judgment you were trying to avoid.

Conservative, the pre-written value test is the best idea of the last round, but it needs one repair. The $160 to $165 central value is the status-quo and persistence case. A bad guide with opex still rising is worse than that, so the conditional value has to sit below it. If you reuse $160 to $165, a bad print takes the stock into the mid-150s, below your test value, and the rule says hold every time. That quietly deletes the cut. Write a lower number down before the print.

On the re-entry gates, each one makes sense alone. Stacked, they are a quantified opex guide below Q3, reconciled to our GAAP number, a 10-K that doesn't contradict, and price holding. Together they make the last quarter very hard to put back, and a gate can fail for reasons unrelated to the thesis. As I recall, QCOM guides revenue and EPS and talks about opex qualitatively, so a quantified opex number may never arrive. The fallback is to back out the implied operating margin from the revenue and EPS guide and ask whether it's rising from the 16 percent area. The GAAP to non-GAAP reconciliation is also in the release itself, so the basis problem is solved the night of the print and doesn't need the 10-K. I'd keep the 10-K as a check with a time box of about two weeks. If it hasn't landed by then, decide on the release and the call. Staying at 75 instead of 100 costs roughly a point of standard allocation in drift, so I'm not casual about it, but a gate that can't be passed is just a cap. Also, "below the Q3 level" is necessary but not sufficient. Q3 was the peak, and $3.6B would still be about 20 percent above a year ago. We want opex falling and margin recovering.

On two-thirds versus half, I side with Conservative on "quantified" and with Aggressive that the filing is the place to check. Concretely, the 10-Q has to show that identifiable one-time items explain most of the roughly $260M step-up from Q2 to Q3. It also has to show that the $991M of operating cash flow is explained by items we can name and expect to reverse. If either is unclear, stay at half. The gap between half and two-thirds is a sixth of standard, about two points of gap exposure, so decide it once before the first tranche and don't revisit. The wash-sale point is fair. It only bites on lots sold at a loss, so choose lots deliberately and ask a tax person, but I wouldn't change the target for it.

Here is what I'd run, in shares of a standard allocation, since I don't know anyone's holdings or basis. Today is Wednesday, so the next two sessions are Thursday and Friday. Friday is monthly expiration, with those $182.50 calls expiring, so the tape will be noisy. Sell about half the trim near 172 to 173 across those two sessions, and don't hold the first piece hostage to a bounce if the stock trades lower. Work the rest on limits up to about 178. Sell whatever is left at market by the close on Monday the 26th, ahead of the FOMC on the 27th and 28th (verify that date), or two sessions before a confirmed print if that's earlier. A daily close below 166.9 finishes any unsold trim and cancels any bid, but doesn't push you below half. A close above 194.48 means reassess, not stop out. Use one bid of about 10 percent, active only once the trim is done, so you're never buying and selling the same shares, and off at the deadline. If you're flat, stay flat.

After the print, a good number with the stock holding means 75 percent once the first full session settles. The last quarter goes back on the gates above, with the fallbacks. A good print where the stock sells off, or a bad print where it holds, means staying at half and not chasing. On a bad guide with opex still rising, don't touch the gap. On days two through five, cut toward a quarter only if the stock is still above the lower value you wrote down beforehand. Sell whatever is unfilled at market on day five.

That keeps half the upside and halves the damage from a 10 to 12 percent gap. It doesn't depend on a bounce, a resolved cash story, or a macro call. The aggressive version still leans on the cash bear case, which the filings can't yet settle. The conservative version keeps adding conditions to a position the evidence doesn't ask us to shrink further. The middle path is a half position, a hard deadline, and rules written before the print.

FINAL TRANSACTION PROPOSAL: SELL Neutral Analyst: The pre-print plan is settled. Everyone has the same shape: about half of standard, the first piece sold Thursday and Friday, limits up to 178, market by the close Monday the 26th or two sessions before a confirmed date, and a 10% bid that's nearly moot. 194.48 is a reassessment level, and a close below 166.9 finishes the trim without pushing below half. The remaining risk is in the post-print rules, because we'll be applying them in a fast market, so that's where I'll push.

First, an error of mine. Conservative is right that my margin fallback was bad, and Aggressive built the full-size rule on it. The December quarter is the seasonally strong one. Take revenue 4% below last year's $12.25B, gross margin at Q3's 53.1%, and opex frozen at $3.65B. That gives about $2.6B of operating income, a 22% margin. A test asking whether margin is rising from 16% passes that, and nobody has cut a dollar. The growth-rate version flatters too: $3.65B against last December's $3.32B is plus 10%, which looks like a big slowdown from plus 22% purely because of the base. Dollars are the right unit. Last year's implied opex barely moved across December, March and June, at roughly 2.95, 2.92 and 3.00. Seasonality therefore doesn't distort a sequential dollar comparison the way it distorts margin. Aggressive, drop "implied margin rising" as a gate.

Conservative, your dollar test as written has two problems. The first is basis. As I recall, the guide is non-GAAP, which excludes stock comp, while our $3.65B is a GAAP figure derived by subtraction. A $3.5B line on our basis can't be applied to an implied number on theirs. The second is noise. Backing opex out of a guide needs a revenue midpoint, a gross margin assumption and an EPS midpoint. One point of gross margin on about $11.8B is roughly $120M, and a ten-cent EPS range is another $120M or so. The error band is as large as the $150M move you're trying to detect.

So I'd use the least-derived numbers first. One is the September quarter's actual reported cost lines against Q3's $3.65B. The other is the guide on the release's own basis, measured sequentially against that same quarter's actual. Then I'd read it in three zones, clearly down, roughly flat or clearly up, and act only on the ends. The middle means you stay where you are.

That brings me to your timer. You wrote that the last quarter goes on when implied opex is about $3.5B or lower, or at ten sessions, whichever comes first. In the good-print branch, if the opex test never passes, session ten still takes us to full size. The gate becomes an accelerator, and the clock supplies the answer. A time limit should force a decision, not make it. At ten sessions, decide from the release, the call and the filing. If the evidence is the middle zone, the decision is to stay at 75%. That costs about a point of drift, which is cheaper than full size on a print where cost progress never showed up. I'd also write down that a revenue and EPS beat with flat opex is not a good print for this purpose.

Aggressive, you've earned one thing. You said the plan doesn't depend on the cash bear case, and you're right. Once the working-capital argument is gone, what's left is opex growing +12%, +16% and +22% against falling revenue, a modest valuation edge, and gap size. Earlier I framed you as leaning on cash, and that was unfair.

On the rest, the $150 is a fair judgment and I'm glad it's written down. But as Conservative showed, it means "cut unless the stock has already fallen 13%." Call it what it is, a post-gap sale of a quarter of standard somewhere between 150 and the mid-160s, worth a point or two. It's not a valuation test. The missing piece is the mirror image. If you'll write a bad-case number, write a good-case number too, so after a good print you know whether to step up or whether the gap already paid for it. Otherwise the downside rules are tight and the upside is discretionary, which is where people chase. "Holds the post-print level" also needs a definition. I'd say no close below the first settled session's close for three sessions.

Conservative's gap check is the most useful new fact. February opened 10.7% below the prior close and July about 5.9% below. Both were down, and the April move up isn't measurable, so that's two data points. Ten to twelve percent is a stress figure, and what we can actually see averages closer to 8%. That makes the protection from halving about four points of standard, not five or six, against an edge of two to three and a half. It's still a good trade, but less lopsided than we've been saying. It's another reason not to go below half and not to stack conditions. Check the options-implied move once the date is confirmed. It's a sanity check on the loss we've agreed to, not a reason to redo the target.

Here's the plan, in shares of a standard allocation. If you're full, read the 10-Q first and decide once between half and two-thirds. Go to two-thirds only if named one-time items explain most of the roughly $260M opex step and nameable, reversible items explain the $991M of operating cash flow. Sell the first piece Thursday and Friday without waiting for a bounce, and work the rest on limits up to about 178. Sell whatever is left at market by the close Monday the 26th, or two sessions before a confirmed print. Look up last year's 10-K filing date on EDGAR, because if it lands within days of the release, the filing-timing argument disappears.

After the print, read reported September-quarter opex first, then the guide on the release's basis. On a good read with the stock holding, go to 75% after the first settled session. Full size needs clearly lower opex, a call that supports it, and a filing that doesn't contradict it. At ten sessions, decide on the evidence, and the middle zone means staying at 75%. On a bad read, do nothing on gap day. On days two through five, cut toward a quarter only if the guide shows opex clearly up and the stock is still above your written bad-case number, and sell anything unfilled on day five. A good print that sells off, or a bad print that holds, means staying at half. If you're flat, stay flat.

FINAL TRANSACTION PROPOSAL: SELL

V. Portfolio Manager Decision

Portfolio Manager

Rating: Underweight

Executive Summary: Underweight QCOM. If you hold it, trim to about 50% of a standard allocation. Sell the first piece near $172-173 on Thursday and Friday without waiting for a bounce, place limit sells for the rest up to about $178, and sell anything unfilled at market by the close on Monday Oct 26 (or two sessions before a confirmed earnings date, if earlier); if you are flat, stay flat and place no bids before the print. Control risk through position size, not stops: a daily close below $166.9 only finishes the trim, a close above $194.48 means reassess rather than stop out, and the reduced position rides through the Q4 FY26 print, with post-print rules written in advance for the next 1-3 months.

Investment Thesis: DECISION: Underweight, not Sell or Hold. All three risk analysts and the Research Manager ended at the same call: sell as a trim to about half, no exit, no short. The bear case won every contested valuation and trend point. The bull's remaining arguments argue against Sell, not for Hold: the decline is opex-driven rather than a broken franchise, the balance sheet is sound (D/E 0.55x, current ratio 2.02, dividend about 40% of FCF), and the Arm verdict reduces license risk.

EVIDENCE THAT DECIDED IT. (1) Operating trend. Revenue growth went +5.0%, -3.5%, -4.0% year over year. Implied opex went $3.32B, $3.39B, $3.65B, which is +12%, +16%, +22%. Operating income fell 5%, 26% and 41%. Operating margin dropped from 30.5% to 16.3%, and gross margin fell three straight quarters to 53.1%. The Aggressive analyst's final framing holds: the trim rests on opex, a modest valuation edge and gap size. It does not need the unresolved cash story. (2) Valuation. The 16.9x forward P/E sits on $10.20 of EPS whose basis is unknown. The best clean GAAP Q4 scenario gives about $7.7-7.9 of EPS, or about 22x. Once revenue is put into the model, the status-quo case is worth about $165 and the persistence case about $160. At $172.62 the stock already pays for opex normalization. The debate corrected the FCF framing: it is two accelerating year-over-year declines (+2.5%, -18%, -81%), not four. FY26 FCF of roughly $9.3B on seasonal scaling (range about $7.3-10B) implies about a 5% yield. That is real support, but below the 5.6% headline. Cash is down about $1.0B from the Sep-2025 base, with a $2.3B reconciliation gap, so treat it as a monitoring item. (3) Technicals. Weekly and daily SuperTrend are DOWN. MACD has made 13 lower readings and is below zero. RSI is 42.36 with no washout. Price closed below the 50-SMA (173.98) and the 10-EMA (177.99), and OBV is falling with price. The offsets are a monthly SuperTrend still UP and price above the 200-SMA (168.04) and the twin 171.02 lows. (4) Event asymmetry. The measurable earnings-style gaps were -10.7% in February and -5.9% in July. Halving the position cuts gap damage by about 4-6 points of a standard allocation, against an edge of about 2-3.5 points. That is a positive-expectancy cut in variance, but a modest one, and it sits inside model error (one turn of multiple is about $8). That is why this is Underweight and not Sell. The Conservative analyst's proposal to cut to a quarter on a close below 166.9 was rightly withdrawn: the level is within one ATR (7.06), so the rule would sell the low.

EXECUTION. Read the June 10-Q first. Hold two-thirds instead of half only if named one-time items explain most of the roughly $260M Q2-to-Q3 opex step and reversible items explain the $991M of operating cash flow. Decide that once. The research plan's $176-181 limit zone was lowered to $175-178 because the last bounce failed at 180.78. The Oct 26 deadline avoids forced selling into the FOMC, which is recalled as Oct 27-28; verify it. Drop the manager's 75% rebuild bids at $152-158, because resting bids add exposure into the event the trim is meant to reduce. US taxable holders should choose lots deliberately to avoid wash sales.

POST-PRINT RULES. Judge cost progress in dollars, not margin. December-quarter seasonality flatters margin: revenue down 4%, gross margin at 53.1% and opex frozen at $3.65B still prints about a 22% margin. Compare reported September-quarter opex and the guide, on the release's own basis, against Q3's $3.65B. A revenue and EPS beat with flat opex does not count as a good print. Good print: go to 75% after the first settled session if the stock holds (no close below that session's close for three sessions). Go to 100% only if opex is clearly lower, at roughly $3.4-3.5B, revenue is -2% or better, the forward EPS basis is stated, and the filing does not contradict the release. At ten sessions, decide on the evidence; an ambiguous read means staying at 75%. Bad guide with opex still rising: do nothing on gap day. On days 2-5, cut toward 25% only if the stock is still above the pre-written bad-case value of about $150 (20x the $7.50 GAAP run-rate), and sell anything unfilled at market on day 5. A good print that sells off, or a bad print that holds, means staying at half. An eroded Arm verdict is a reason to trim further. Consider Overweight only if FY27 guidance turns revenue positive. A daily close above 194.48 triggers reassessment.

PRICE TARGET is a valuation objective. The midpoint of the revenue-adjusted central values, $160 (persistence, $42.5B revenue) and $165 (status quo, -1.3% revenue), is $162.5. Cross-check: about 21x times $7.75, the midpoint of the $7.7-7.9 clean GAAP EPS range, is about $162.75. The target implies about 5.9% downside from $172.62.

DATA GAPS: the earnings and 10-K dates are unverified; the forward EPS basis is unknown; one-time items in Q3 opex are unknown; Arm appeal status is unknown; there is a $2.3B cash-flow reconciliation gap; there is no 10-year yield data; today's bar may be incomplete; the caller's holdings and tax basis are unknown.

Current Price: 172.62

Price Target: 162.5

Confidence: Medium

Time Horizon: 1-3 months